Document:

Exhibit 10.23

 

[*Confidential Treatment has been requested as to certain
portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk [*], has been filed separately
with the Securities and Exchange Commission.]

 

CONFIDENTIAL

 

LICENSE AND SUPPLY AGREEMENT

 

This License and
Supply Agreement (this “Agreement”), dated as of December 20th, 2017 (“Effective Date”),
is made by and between Celsee, Inc. (“Celsee”), a Delaware corporation having a business address at 46701
Commerce Center Dr., Plymouth, MI 48170, USA, and Zomedica Pharmaceuticals Corp. (“Zomedica”), a
Canadian corporation having a business address at 1250, 639 – 5th Avenue SW, Calgary, Alberta, T2P 0M9 Canada.
Each of Celsee and Zomedica may be referred to herein as a “Party” or together as “Parties”.

 

WHEREAS:

 

		A.	Celsee has proprietary microfluid technology for processing samples and isolating circulating tumour
cells (“CTCs”) for Oncology/Immuno-Oncology life science and clinical research applications including for diagnostic
purposes and develops, manufactures, and markets innovative, integrated microfluidic systems for same.

 

		B.	Zomedica is a veterinary pharmaceutical and health care solutions company creating innovative products
for companion animals (canine, feline and equine) including veterinary-approved drugs, novel drug-delivery technologies, diagnostics,
and which has expertise and know-how in developing products for applications in the veterinary field.

 

		C.	Pursuant to the Collaborative Research Agreement of January 3, 2017, the Term Sheet negotiated
by the Parties and the Mutual Non-disclosure Agreement of February 5, 2016, the Parties wish to enter into this Agreement
to develop consumable CTC assay materials for detection of companion animal cancers from blood with such consumables consisting
of at least the Celsee Immunochemistry Consumable Package (without antibodies) and which may also include Zomedica antibody sets
and/or biomarkers (inclusive of antibodies, the “CTC Consumable Package”).

 

NOW THEREFORE, in consideration
of the foregoing premises and the mutual covenants set forth in this Agreement, the consideration given, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound,
hereby agree as follows:

 

		1.	Definitions

 

The following terms and their correlatives
have the following meanings:

 

1.1             
“Affiliate” means any corporation or other entity which directly or indirectly controls, is controlled
by or is under common control with a Party, for so long as such control exists. For the purposes of this Section 1.1 (“Affiliate”),
“control” shall mean: (i) in the case of

 

    
	 	1	 
	 	Confidential	 

     

    

[*Confidential Treatment
has been requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with
an asterisk [*], has been filed separately with the Securities and Exchange Commission.]

 

any corporate entity,
direct or indirect ownership of more than fifty percent (50%) of the stock having the right to vote for the election of directors
thereof or (ii) in the case of any non-corporate entity, direct or indirect ownership of more than fifty percent (50%) of
the equity or income interest therein.

 

1.2             
“Agreement” has the meaning set forth in the Preamble and includes this Agreement and any schedules,
appendices and development plan(s).

 

1.3             
“Arbitrator” has the meaning set forth in Section 15.4.

 

1.4             
“Background Intellectual Property” means the Intellectual Property created or Controlled by a Party prior
to the Effective Date of this Agreement.

 

1.5             
“Bankruptcy Laws” has the meaning set forth in Section 13.3(b)(i).

 

1.6             
“BIA” has the meaning set forth in Section 13.3(b)(i).

 

1.7             
“Business Day” means any day that is not a Saturday, Sunday, or statutory holiday in the state of Michigan.

 

1.8             
“Calendar Quarter” means a quarter of the year, the first Calendar Quarter ending March 31 of each
year, the second on June 30 of each year, the third on September 30 of each year and the fourth on December 31 of each
year.

 

1.9             
“Calendar Year” means the calendar year, commencing at the beginning of the first Calendar Quarter and
ending the end of the fourth Calendar Quarter.

 

1.10         
“Celsee Controlled Patent Right” means a Patent Right that is Controlled by Celsee.

 

1.11         
“Celsee Controlled Technology” means Technology Controlled by Celsee including Celsee Owned Intellectual
Property, and Celsee Controlled Patent Rights.

 

1.12         
“Celsee Core Technology” means the Celsee CTC Platform Technology, collectively with the Celsee Immunochemistry
Consumable Package.

 

1.13         
“Celsee’s CTC Platform Technology” means Celsee’s proprietary instruments (e.g., [*]) and
software and Technology related thereto.

 

1.14         
“Celsee Immunochemistry Consumable Package” means the package of proprietary immunochemistry consumables
that Celsee has previously developed for use with the Celsee CTC Platform Technology.

 

1.15         
“Celsee Field” means all fields of use other than the Zomedica Field, including all human health and
human diagnostic applications, veterinary research, and veterinary clinical diagnostics other than cancer.

 

    
	 	2	 
	 	Confidential	 

     

    

1.16         
“Celsee Indemnitees” has the meaning set forth in Section 12.2.

 

1.17         
“Celsee Owned Intellectual Property” is the Intellectual Property owned by Celsee as set out in Section
8.2.

 

1.18         
“Celsee Parties” has the meaning set forth in Section 12.1(a).

 

1.19         
“CCAA” has the meaning set forth in Section 13.3(b)(i).

 

1.20         
“Change of Control” means, with respect to a Party, (a) a merger, reorganization, or consolidation
of a Party with or into any Third Party, or any other corporate reorganization involving such a Third Party, that results in those
persons or entities that are stockholders of a Party immediately prior such merger, reorganization, or consolidation owning less
than fifty percent (50%) of the surviving entity’s voting power immediately after such merger, reorganization, or consolidation,
(b) a change in the legal or beneficial ownership of fifty percent (50%) or more of the combined voting power of the outstanding
securities of a Party (whether in a single transaction or series of related transactions), where immediately after giving effect
to such change, the legal or beneficial owner of more than fifty percent (50%) of the voting securities of a Party is a Third Party
or (c) the sale, transfer, lease, license or other disposition to a Third Party of all or substantially all of a Party’s
business or assets to which this Agreement relates in one or a series of related transactions; provided that a “Change of
Control” shall not include any Change of Control required by a government or the requirements of applicable Law or a transaction
or series of transactions undertaken principally undertaken for bona fide equity financing purposes.

 

1.21         
“Clinical Validation” means the successful testing by Zomedica with at least one veterinary cancer type
of the customized CTC Consumable Package and Celsee Platform Technology for use in the Zomedica Field, across a sample of sufficient
size and rigor to support the diagnostic sensitivity and specificity of the product for marketing purposes as determined by Zomedica
in its sole discretion.

 

1.22         
“Collaboration Product” means a veterinary clinical cancer diagnostic product developed pursuant to the
Development Plan or this Agreement including CTC Consumable Package(s) and Celsee’s CTC Platform Technology modified or adapted
for veterinary cancer diagnostics.

 

1.23         
“Commercially Reasonable Efforts” of a Party means, with respect to an obligation of a Party to accomplish
an objective under this Agreement, the efforts and resources comparable to those undertaken by a veterinary pharmaceutical company
of comparable size and resources in the case of Zomedica or a biopharmaceutical or biotechnology company of comparable size and
resources in the case of Celsee relating to the research, development or commercialization of a similar product owned by such company,
or to which such company has exclusive rights, with comparable market potential and is at a similar stage in its lifecycle. For
this purpose, all relevant factors, as measured by the facts and circumstances at the time such efforts are due, shall be taken
into account, including, as applicable and without limitation, stage of development; efficacy and safety relative to competitive
products in the marketplace; actual or anticipated Regulatory Approval; labeling; the nature and extent of market exclusivity (including
patent coverage, proprietary position and regulatory exclusivity), product pricing and reimbursement; and the cost and time required
for and likelihood of obtaining Regulatory Approval and commercializing a product.

 

    
	 	3	 
	 	Confidential	 

     

    

1.24         
“Confidential Information” has the meaning set forth in Section 9.1 (Confidentiality; Exceptions).

 

1.25         
“Contract Interest Rate” means the lesser of:

 

(a)               
the Wall Street Journal prime rate of interest ; and

 

(b)              
the maximum rate permitted by Michigan Law.

 

1.26         
“Control” means, with respect to any Information, Patent Right or other intellectual property right,
the possession (whether by ownership or license) by a Party or its Affiliate of the conditional or unconditional ability to grant
to the other Party access, ownership, a license or a sublicense as required herein (including without limitation pursuant to a
power of attorney) to such Information, Patent Right, or other intellectual property right without violating the terms of any agreement
or other arrangement with any Third Party in existence as of the Effective Date. In the case that the ability to grant is conditional
(as with certain sublicenses), Control will require that the other Party be able to and agrees to satisfy such condition(s).

 

1.27         
“Covers” or “Covering”, with reference to a Patent Right, means that the making, using,
selling, offering for sale or importing of a composition of matter, process or other material or practice of a claimed method would,
but for ownership of or a license under such Patent Right, comprise an infringement (including contributory or inducement) of a
Valid Claim (or, if such Valid Claim has not issued, if such Valid Claim were to issue), within such Patent Right in the country
in which such activity occurs.

 

1.28         
“CTC Consumable Package” means a package of CTC assay consumables for detection of veterinary cancers
from blood, with such kits consisting of at least the Celsee Immunochemistry Consumable Package (with reagents optimized for veterinary
use and without antibodies), and which may also include Zomedica antibody sets and/or biomarkers and designed to run on Celsee’s
CTC Platform Technology as modified for the veterinary cancer diagnostics market.

 

1.29         
“Companion Animal” as used herein means canines (dog), felines (cat) and equines (horses).

 

1.30         
“Cost of Manufacture” means the direct (materials, labor, freight, quality testing) and indirect (production
facility costs such as utilities, and equipment depreciation) costs without mark up incurred by Celsee in manufacturing the Celsee
Immunochemistry Consumable Package.

 

1.31         
“Development” or “Develop” means non-clinical and clinical development activities
pertaining to a Collaboration Product, including, but not limited to, antibody identification and testing, protocol optimization,
software optimization, process and manufacturing development, quality assurance and quality control development, statistical analysis,
and clinical studies.

 

    
	 	4	 
	 	Confidential	 

     

    

1.32         
“Development Plan Budget” has the meaning set forth in Section 2.1.

 

1.33         
“Development Plan” means the written plan for Developing and validating Collaboration Products, as set
forth in the Development Plan Schedule, Schedule A, attached hereto, and which may be amended from time to time in
accordance with the terms of this Agreement.

 

1.34         
“Dispute” has the meaning set forth in Section 14.1.

 

1.35         
“Dollars” means U.S. Dollars, and “$” shall be interpreted accordingly.

 

1.36         
“Effective Date” has the meaning set forth in the Preamble.

 

1.37         
“Force Majeure” has the meaning set forth in Section 15.7 (Force Majeure).

 

1.38         
“Indemnified Party” has the meaning set forth in Section 12.3.

 

1.39         
“Indemnifying Party” has the meaning set forth in Section 12.3.

 

1.40         
“Indemnify” has the meaning set forth in Section 12.1.

 

1.41         
“Information” means all information not generally known to the public, including tangible and intangible
techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, conclusions,
skill, experience, test data and results (including pharmacological, toxicological, manufacturing, and clinical test data and results),
analytical and quality control data, results or descriptions, software and algorithms, including works of authorship and copyrights.

 

1.42         
“Insolvency Event” has the meaning set forth in Section 13.3(a).

 

1.43         
“Insolvent Party” has the meaning set forth in Section 13.3(b)(iii).

 

1.44         
“Intellectual Property” means Patent Rights, trade secrets, copyrights (and associated moral rights),
trade-marks (and associated goodwill), industrial designs, domain names, Know-How and other forms of proprietary or industrial
rights pertaining to inventions, original works and other forms of intellectual property.

 

1.45         
“Know-How” means all techniques, technical information, technology practices, research tools and platforms,
trade secrets, inventions (whether patentable or not), methods, processes of manufacture, methods for isolation of CTCs, data and
results (including pharmacological, toxicological and preclinical and clinical test data and results), analytical and quality control
data, software including in source code or object code form) and algorithms now or hereafter Controlled by the Parties.

 

    
	 	5	 
	 	Confidential	 

     

    

1.46         
“Law” means, individually and collectively, any and all applicable laws, statutes, regulations, treaties,
judgments, decrees, ordinances, rules, rulings, directives, and administrative circulars, (and whether or not having the force
of law) all applicable consents, approvals, by-laws, permits, authorizations, guidelines, orders and policies of any kind whatsoever
of any governmental authority or Regulatory Authority within the applicable jurisdiction.

 

1.47         
“Losses” has the meaning set forth Section 12.1.

 

1.48         
“Materials” means any tangible instrument, property, chemical or biological material.

 

1.49         
“Party” and “Parties” has the meaning set forth in the Preamble.

 

1.50         
“Patent Right” means any and all rights in patents which are defined as:

 

(a)               
patents;

 

(b)              
pending patent applications, including, all provisional applications, substitutions, continuations, continuations-in-part,
divisions and renewals and all patents granted thereon;

 

(c)               
all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration
mechanisms, including, supplementary protection certificates or the equivalent thereof;

 

(d)              
inventor’s certificates;

 

(e)               
any other form of government-issued right substantially similar to any of the foregoing; and

 

(f)               
all U.S. and foreign counterparts of any of the foregoing, collectively, (a) to (f) being “Patents”.

 

1.51         
“Post Term Period” has the meaning in Section 13.5.

 

1.52         
“Prosecution and Maintenance” means, with respect to a Patent Right, the preparing, filing, and prosecuting
of patent applications and maintenance of patents, as well as re-examinations, and reissues, with respect to such patents, together
with the conduct of interferences and the defense of oppositions with respect to the particular patent application or patent; and
“Prosecute and Maintain” have the correlative meaning.

 

1.53         
“Regulatory Approval” means all approvals (including any applicable governmental price and reimbursement
approvals), licenses, registrations, and authorizations of any federal, national, multinational, state, provincial or local Regulatory
Authority, department, bureau and other governmental entity that are necessary and sufficient for the marketing and sale of a product
or associated activities in a country or group of countries in the Territory. Regulatory Approval includes any required pricing
and reimbursement approval for the Collaboration Product.

 

    
	 	6	 
	 	Confidential	 

     

    

1.54         
“Regulatory Authority” means, with respect to a country, the regulatory authority or regulatory authorities
of such country with authority over this Agreement and activities contemplated hereunder including the testing, manufacture, use,
storage, importation, promotion, marketing, pricing or sale of a diagnostic product or Collaboration Product in such country.

 

1.55         
“Senior Executives” has the meaning set forth in Section 14.1.

 

1.56         
“Taxes” means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any
nature (including any interest thereon).

 

1.57         
“Technology” as used herein includes all Intellectual Property and associated Rights, all Information,
Confidential Information, Know-How and Materials.

 

1.58         
“Term” has the meaning set forth in Section 13.1.

 

1.59         
“Territory” means the world.

 

1.60         
“Third Party Claim” has the meaning set forth in Section 12.1.

 

1.61         
“Third Party” means any entity other than a Party or an Affiliate of a Party.

 

1.62         
“United States” or “U.S.” means the United States of America, including its
territories and possessions, the District of Columbia and Puerto Rico.

 

1.63         
“Valid Claim” means, with respect to a particular country:

 

(a)               
any claim of an issued and unexpired Patent Rights in such country that:

 

(i)                
has not been held permanently revoked, unenforceable or invalid by a decision of a court or governmental agency of competent
jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal; and

 

(ii)              
has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise
in such country; or

 

(iii)            
a claim of a pending patent application where such claim has been pending for a period of ten (10) years or less.

 

1.64         
“VAT” means the goods and services tax and the harmonized sales tax or other value added tax imposed
by Applicable Laws.

 

1.65         
“Zomedica” shall have the meaning set forth in the Preamble.

 

1.66         
“Zomedica Field” means all veterinary cancer diagnostic applications, including but not limited to Companion
Animals.

 

1.67         
“Zomedica Owned Intellectual Property” means Intellectual Property owned by Zomedica as noted in Section
8.

 

    
	 	7	 
	 	Confidential	 

     

    

1.68         
“Zomedica Indemnitees” has the meaning set forth in Section 12.1.

 

1.69         
“Zomedica Parties” has the meaning set forth in Section 12.2(a).

 

1.70         
“Schedules” The following schedules are (or will be once agreed to between the Parties) attached to and
form part of this Agreement:

 

Schedule
A – Development Plan and Budget

 

Schedule
B – Celsee Patent Rights

 

Schedule
C – Compliance Schedule/Code of Conduct

 

Schedule
D – Customer Service Agreement

 

Schedule
E – Quality Control

 

Schedule
F – Private Placement And Registration Rights Rider

 

1.71         
Construction.

 

(a)               
The definitions of the terms herein apply equally to the singular and plural forms of the terms defined.

 

(b)              
Whenever the context may require, any pronoun includes the corresponding masculine, feminine and neuter forms.

 

(c)               
The words “include”, “includes” and “including” are deemed to be followed by the phrase
“without limitation.”

 

(d)              
The word “will” is construed to have the same meaning and effect as the word “shall.”

 

(e)               
Unless the context requires otherwise,

 

(i)                
any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such
agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions
on such amendments, supplements or modifications set forth herein or therein),

 

(ii)              
any reference to any Laws herein will be construed as referring to such Laws as from time to time enacted, repealed or amended,
any reference herein to any person will be construed to include the person’s permitted successors and assigns,

 

(iii)            
the words “herein”, “hereof” and “hereunder”, and words of similar import, will be construed
to refer to this Agreement in its entirety and not to any particular provision hereof, and

 

    
	 	8	 
	 	Confidential	 

     

    

[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

(iv)            
all references herein to Articles, Sections or Schedules, unless otherwise specifically provided, will be construed to refer
to Articles, Sections or Schedules of this Agreement.

 

		2.	Development Plan

 

2.1             
Development Plan and Development Plan Budget. The Development Plan is attached hereto as Schedule A. The Development
Plan sets forth the obligations, milestones, development timing and a detailed budget of the financial commitments of each of the
Parties for same (such budget, the “Development Plan Budget”) in connection with the development of Collaboration Products
and modifications to the Celsee CTC Platform Technology necessary to run veterinary clinical cancer diagnostic tests using the
CTC Consumable Package(s). The Development Plan also sets forth the obligations of each of the Parties in terms of:

 

[*]

 

2.2             
Development Plan Project Management. The Parties shall each perform the activities allocated to it in accordance
with the Development Plan.

 

(a)               
Designation of Representatives. Stephanie Morley of Zomedica and Kalyan Handique of Celsee will be the initial “Project
Coordinators” under this Agreement. The Project Coordinators will be responsible for day-to-day communications between the
Parties regarding the subject matter of this Agreement. Either Party may change its Project Coordinator at any time and from time
to time by giving the other Party written notice.

 

(b)              
Responsibilities of Project Coordinators. Each Project Coordinator will be responsible for: (a) monitoring the schedules
and progress of work under the Development Plan and this Agreement; (b) receiving and submitting requests for information and/or
assistance; (c) determining whether a request he or she receives for information and/or assistance from the other Project Coordinator
is necessary for the other Parties to complete a specific project; (d) supervising and recording the exchange of confidential information.

 

(c)               
Meetings. The Project Coordinators will meet as necessary (but at least bi-monthly) to discuss the progress of the
development effort and, if applicable, to exchange information regarding the Development Plan.

 

2.3             
Changes to Development Plan. If the parties mutually determine that the development undertaking contemplated by the
Development Plan is not technically or commercially feasible, the Development Plan may be subject to change based on scientific,
technology or marketing considerations. In such event, the Parties agree to negotiate in good faith and in a reasonable manner
to reach agreement on any such changes. Any material changes to the Development Plan must be agreed to by both Parties. If the
Parties are unable to agree on changes to the Development Plan, the matter shall be resolved in accordance with Dispute Resolution
set forth in Section 15.

 

    
	 	9	 
	 	Confidential	 

     

    

[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

2.4             
Diligence. Each Party shall use Commercially Reasonable Efforts to perform (itself or through its Affiliates
or by permitted subcontracting) its respective obligations under the Development Plan, and shall reasonably cooperate with and
provide reasonable support (at the other Party’s expense) to the other Party in such other Party’s performance of its
responsibilities under the Development Plan. The Parties acknowledge and agree, however, that no outcome or success is or can be
assured and that failure to achieve desired results do not in and of itself constitute a breach or default of any obligation in
this Agreement.

 

2.5             
Personnel. Each Party agrees that it shall assign qualified employees, consultants, and subcontractors to perform
the research and development tasks that have been assigned to it under the Development Plan. Each Party shall cause all (i) employees
to be subject to confidentiality and proprietary invention agreements or policies at least as restrictive as the terms set forth
in this Agreement and (ii) all non-employee persons and entities performing work under this Agreement or the Development Plan on
such Party’s behalf to execute a confidentiality and proprietary rights agreement in a form that is consistent with the agreements
in effect between the Parties. All such research and development work to be performed by a Party shall take place at said Party’s
principal place of business or at such other location as said Party deems advisable. Each Party will be responsible for any compensation
or payment to its employees, contractors or agents in connection with the invention of any Patent Right or other Intellectual Property.
In performing their activities hereunder, each Party shall comply with the Compliance Schedule/Code of Conduct attached as Schedule
C and incorporated by reference herein.

 

2.6             
Equipment. Except as expressly stated in the Development Plan, each Party shall be responsible for obtaining all
laboratory and production equipment, computers, software, machinery, and supplies that it shall require to perform its tasks under
the Development Plan. All equipment or instruments will be owned, and title will be retained, by the Party who provided such equipment
or instruments in connection with the Development Plan.

 

2.7             
Reporting. The Parties agree that they shall use Commercially Reasonable Efforts to inform each other as soon as
possible of events that may materially affect the timetable for completion of assigned tasks under the Development Plan. When a
Party anticipates a delay, said Party will inform the other Parties by telephone, facsimile, or electronic transmission of the
reasons, the milestones affected and the proposed new dates.

 

2.8             
Exclusivity. During the Term or in the event this Agreement is terminated by Zomedica as a result of an uncured
material breach by Celsee pursuant to Section 13.2(a)(i) for a period of [*] thereafter, Celsee and its Affiliates shall not,
directly or indirectly, without the prior written consent of Zomedica:

 

(a)               
conduct or continue any research or development of any new or existing products for use in Zomedica’s Field, alone
or in collaboration with or for the benefit of any

 

    
	 	10	 
	 	Confidential	 

     

    

(b)              
Third Party (including any governmental agency) for the purposes of commercialization, use, manufacture or distribution
of Celsee Immunochemistry Consumable Packages in the Zomedica Field; provided however that this prohibition shall not apply solely
to research in the Zomedica Field conducted pursuant to funding received from government grants;

 

(c)               
except pursuant to the Development Plan, Develop or commercialize any product in the Zomedica Field, alone or in collaboration
with or for the benefit of any Third Party (including any governmental agency);

 

(d)              
collaborate with, license, enable or otherwise authorize or grant rights to any Third Party to use, develop, commercialize
or manufacture products in the Zomedica Field, other than Third Party subcontractors to the extent permitted under Section 2.9,
or enter into any agreement, amendment to an existing agreement or option to do any of the same; or

 

(e)               
grant any right to any Third Party in the Zomedica Field that would impair or conflict in any way with any of the rights
granted to Zomedica under this Agreement; and

 

(f)               
notwithstanding any of the foregoing and for clarity, subject to Section 9.1(b) and Section 9.2, Celsee, its Affiliates,
and all other non-profit academic research institutions with whom it may contract from time to time, shall not be restricted from
conducting any non-clinical Development activities for non-commercial purposes or for profit research with contract research organizations
for the sole purpose to develop and commercialize products outside the Zomedica Field, including veterinary research, veterinary
clinical diagnostics for indications other than cancer, and human clinical research.

 

2.9             
Permitted Subcontracting.

 

(a)               
Each Party may subcontract any of its activities to be performed under the Development Plan to a Third Party or to an Affiliate
of the Party, provided that any such Third Party or Affiliate shall have entered into a written agreement with such Party that
includes terms and conditions protecting and limiting use and disclosure of Confidential Information, Materials and Information
of the other Party at least to the same extent as under this Agreement or, in the case of such Affiliate, such Affiliate is subject
to similar obligations of non-use and non-disclosure, and requiring such Third Party or Affiliate, as applicable, and its employees,
contractors and agents to grant such Party Control in and to any Patent Rights, Information and Materials created, conceived or
reduced to practice in connection with the performance of any such subcontracted activities.

 

(b)              
Each Party shall remain responsible and liable for the performance by its Affiliates and subcontractors of its obligations
hereunder, and shall cause its Affiliates and subcontractors to comply with the provisions of this Agreement, including, causing
such Third Parties to make any and all assignments of intellectual property rights generated in carrying out a Party’s obligation
in accordance with the terms of this Agreement.

 

2.10         
Records. Each Party shall maintain, or cause to be maintained, records of its activities under the Development Plan
in sufficient detail and in good scientific manner appropriate for scientific, patent and regulatory purposes, which shall properly
reflect all work included in the Development Plan consistent with its internal procedures and policies.

 

    
	 	11	 
	 	Confidential	 

     

    

2.11         
Materials. Each Party may furnish to the other Party, as reasonably required, samples of Materials. The Party receiving
any Materials shall not distribute or otherwise allow the release of Materials to any Third Party, except for subcontracting, in
each case as permitted hereunder. All Materials delivered to the receiving Party are provided “AS IS”, shall be used
in compliance with all Laws, shall be used solely for the purposes of carrying out the Development Plan and for no other
purpose and shall be used with prudence and appropriate caution in any experimental work because not all of their characteristics
may be known. In regard to the transfer of any Material between the Parties, unless specifically stated otherwise by the transferor
as a condition to a voluntary transfer, such transfer of Material will not be a transfer of ownership to the transferee of the
physical sample being transferred. Such transfer will not exhaust intellectual property rights attached to such Material.

 

		3.	Regulatory Matters

 

3.1             
Zomedica shall:

 

(a)               
be responsible at Zomedica’s expense for all Clinical Validations, regulatory interactions and commercialization activities
(including sale and use of Celsee CTC Platform Technology and CTC Consumable Package(s)) with respect to the Collaboration Product(s)
in the Zomedica Field in the United States and other countries in the Territory as may be required, including establishing and
maintaining the global safety database of adverse events and relevant safety information in the Field for the Collaboration Product(s),
communications and meetings with Regulatory Authorities, seeking and obtaining any necessary Regulatory Approvals (including pricing
approvals); and

 

(b)              
own all regulatory filings relating to Collaboration Product(s).

 

(c)               
share the data from Clinical Validations with Celsee for Celsee’s internal use only. Such data shall be considered
proprietary Zomedica information, and will be subject to any and all confidentiality obligations governing use of confidential
information by the parties.

 

3.2             
Celsee shall:

 

(a)               
provide Zomedica with all necessary documents and information regarding Celsee products, Celsee Immunochemistry Consumable
Package(s), Celsee Platform Technology and such other documents and information reasonably requested by Zomedica and will provide
reasonable assistance in completing Clinical Validation processes and obtaining any necessary regulatory approvals, including by
maintaining a consistent or ‘locked’ design for the Collaboration Products during the validation process(es);

 

(b)              
shall comply with all Laws regarding same including all GMP and GCP requirements and maintain any Regulatory Approvals (including
any site licenses) in good standing so as to enable it to perform its obligations under this Agreement including but not limited
to the manufacture of the Collaboration Products and Celsee Platform Technology.

 

    
	 	12	 
	 	Confidential	 

     

    

[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

		4.	Manufacturing and Supply

 

4.1             
Branding: The Collaboration Product will display branding determined by Zomedica for the veterinary diagnostics market.
To the extent possible and as allowed by applicable Laws, Celsee’s brand will also be displayed on the Collaboration Product
components.

 

4.2             
Manufacturing and Product Supply:

 

(a)               
During the Term, Celsee shall exclusively supply (and Zomedica will purchase exclusively from Celsee) the Collaboration
Products for resale to customers of Zomedica solely for use in the Zomedica Field.

 

(b)              
Zomedica shall issue to Celsee from time to time, purchase orders which shall confirm the quantity and shipping arrangement
for the Collaboration Products. This Agreement shall contain all terms and conditions regarding the sale of Collaboration Products
and any terms in Zomedica’s purchase orders which are inconsistent with the terms of this Agreement shall be of no force
and effect. Delivery Dates for the Collaboration Products will be [*] and for the CTC Consumable Package will be [*] after the
purchase order is delivered to Celsee. Zomedica shall be responsible for supply of the antibody cocktail or biomarkers, if any,
for inclusion in the CTC Consumable Package used in the Collaboration Products at no cost to Celsee. Zomedica shall be responsible
for sales of Collaboration Products to customers, for invoicing customers and for collecting receivables related to Collaboration
Products in a timely fashion. All undisputed invoices for Collaboration Products shall be provided by Celsee to Zomedica following
product shipment and shall be due and payable in full within [*] of the date the invoice is received.

 

(c)               
Celsee will manufacture and supply the Collaboration Products at agreed upon supply prices as noted in Section 7.4 to Zomedica,
which shall be subject to adjustment as provided in this Agreement. All Collaboration Products shall be manufactured in accordance
with Applicable Laws including cGMP and meet all specifications for the Collaboration Products.

 

(d)              
 Within 30 days of the effective date and [*] prior to the commencement of each calendar quarter during the Term and the
Post Term Period, Zomedica shall provide a rolling 12 month forecast of its supply requirements for Collaboration Products (the
“Forecast”) and shall be obligated to purchase the forecasted amounts of the Celsee Platform equipment and CTC Consumable
Package for the most recent [*] of the Forecast (such three months being referred to as the “Binding Forecast”). Celsee
shall at all times maintain sufficient capacity to meet all supply requirements of Zomedica and its customers for the Collaboration
Products based on Binding Forecast. Celsee shall not be obligated to supply the Collaboration Products, CTC Platform or CTC Consumable
Packages in excess of [*] of Binding Forecast amounts, but will use Commercially Reasonable Efforts to meet any such additional
supply requirements. Celsee shall promptly notify Zomedica in writing if at any time Celsee has reason to believe (i) that it will
not be able to fill a purchase order in accordance with the delivery schedule specified therein and pursuant to the terms of this
Agreement or (ii) supply Collaboration Products, the Celsee Platform equipment or CTC Consumable Package in satisfaction of the
most recent Binding Forecast which notice in either event shall provide Zomedica with information on the extent of the expected
shortfall. Upon receipt of such notice, the Parties shall immediately meet and work together in good faith to identify an appropriate
resolution to the supply shortfall.

 

    
	 	13	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

(e)               
Zomedica shall have [*] business days from receipt of each delivery of Collaboration Products to inspect the
delivery for a shortfall, and to inspect the Collaboration Products packaging for visible defects. Zomedica may notify Celsee of
a shortfall, or reject visibly defective Collaboration Products, within [*] days of such inspection. Upon notice to Celsee of a
shortfall or defect, Celsee shall deliver the shortfall amount as soon as commercially possible. Zomedica may request expedited
(e.g., overnight) shipment of such shortfall delivery and Celsee shall be responsible for the cost of such expedited shipment.

 

(f)               
Celsee shall package the Collaboration Products in containers suitable to ensure that the Collaboration Products will not
be damaged in the ordinary course of delivery. Shipment shall be made EXW Celsee’s dock. Celsee shall arrange for the shipment
of the Collaboration Products to Zomedica in accordance with Zomedica’s instructions (e.g., use of Zomedica’s freight
account, insurance, etc.), and Zomedica shall pay the cost of shipping as reflected in the corresponding Collaboration Products
invoice. Celsee will perform, at Celsee’s expense, quality control testing on all Collaboration Products in accordance with
normal industry standards, as detailed in Schedule E. Contemporaneous with each shipment of Collaboration Products hereunder, Supplier
will provide Company with a Certificate of Analysis with respect to such Collaboration Product confirming that the Collaboration
Products have undergone quality control testing.

 

(g)              
Celsee shall promptly notify Zomedica of any anticipated changes to the Collaboration Products or any components thereof,
and shall also notify Zomedica of proposed changes to the Quality Control processes documented in Schedule E. The Parties shall
use commercially reasonable efforts to accommodate and integrate any necessary changes, with the goal of minimizing the commercial
impact on the Collaboration Products.

 

		5.	Marketing, Customer and Product Support

 

5.1             
Zomedica will be solely responsible for marketing the Collaboration Products in the Zomedica Field.

 

5.2             
Zomedica will be responsible for warehousing of the Collaboration Products inventory, and for sales of and shipping of such
products to end customers. The Parties understand and agree that, Celsee’s warehouse will be available for inventory until
[*] following the transfer by Celsee to an automated manufacturing process.

 

5.3             
Once a product is sold to a customer, Zomedica will be responsible for providing training and first-tier customer support.
Celsee will provide training to necessary Zomedica employees, as well as materials to be used in providing training for Zomedica
customers. Any Collaboration Product or software-related support in the United States will be provided by Celsee without charge,
with the parties’ specific support responsibilities as enumerated in Schedule D. Celsee will provide necessary training at
an agreed rate to Zomedica distributors outside the United States.

 

    
	 	14	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

5.4             
Warranty and Limitations.

 

(a)               
Limited Warranty. Celsee shall be responsible for all warranty work, refunds and repairs with respect to the
CTC Platform and shall be entitled to retain all revenues from extended warranty or service contracts in the United States between
Celsee and any customers of Zomedica. Celsee warrants all instruments and Collaboration Products will be free from defects in materials
or workmanship under normal use for a period of [*] from shipment to Zomedica and all consumables will be free from defects in
materials or workmanship under normal use and proper storage conditions for [*] from shipment to Zomedica or the stated Celsee
shelf life for consumables. The warranty shall not apply to any defects directly attributable to antibody sets or biomarkers provided
by Zomedica. In addition, the warranty shall not apply to any Collaboration Product used for a purpose or in a manner for which
it was not intended, which is not used in accordance with instructions for use, which is altered in any way, or which is subject
to misuse, negligence, accident or neglect. Celsee’s obligation with respect to this warranty is limited to the replacement
of defective Collaboration Products after inspection and verification of such defects. Zomedica will responsible to the customer
for any warranty beyond the warranty provided herein.

 

(b)              
Celsee’s warranty obligations under this Section 5.4 are subject to Zomedica’s compliance with the following
procedures:

 

(i)                
The Products are sold by Zomedica in the Zomedica Field.

 

(ii)              
Upon identification of a defect covered under Celsee’s warranty, Zomedica will notify Celsee of the product SKU and
lot number of the allegedly defective Collaboration Product with a description of the problem or defect.

 

(iii)            
Celsee shall notify Zomedica if the allegedly defective Collaboration Product should be returned and, if so, will issue
a Celsee return merchandise authorization (RMA) number with respect to the claim.

 

(iv)            
Any items returned to Celsee under warranty pursuant to an RMA are to be sent freight prepaid. In the event that Celsee
determines that the Collaboration Product need not be returned, the Collaboration Product shall be destroyed by Zomedica or the
customer.

 

(v)              
Celsee shall provide replacement of the returned Collaboration Products that are determined to be defective, in Celsee’s
sole discretion, at no charge to Customer.

 

    
	 	15	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

5.5             
Additional extended warranties in United States can be purchased from Celsee at [*] per instrument per year. Extended warranties
outside the United States will be the responsibilities of Zomedica or its distributors, with any necessary training to be provided
by Celsee. Zomedica shall be responsible for any warranties given to its customers beyond those in Section 5.4. All customer warranties
shall contain customary limitations of liability and damage limitations protecting both Zomedica and Celsee.

 

5.6             
Replacement parts for warranty work performed outside of the U.S. will be provided by Celsee, with the requirement that
any defective parts shall be returned to Celsee as part of the warranty/repair process.

 

		6.	License Grants

 

6.1             
During the Term and the Post Term Period of the Agreement, each Party grants to the other a non-exclusive license for the
Territory in their respective Intellectual Property to the extent necessary to perform their respective obligations under the Development
Plan and to develop and manufacture Collaboration Product(s) and for no other purposes.

 

6.2             
During the Term of this Agreement, Celsee herein grants Zomedica an exclusive (other than during the Post Term Period detailed
in Section 13.5 or as otherwise expressly set forth herein) license in the Territory (even as to Celsee) to all Celsee Controlled
Technology related to the Collaboration Product(s), including the Celsee CTC Platform Technology and CTC Consumable Package(s),
to commercialize, Develop or otherwise exploit, market, sell and distribute of same solely in connection with the Collaboration
Products in the Zomedica Field for veterinary cancer clinical diagnostics. For clarity, any other field of use or applications
other than cancer (veterinary or human), veterinary research or human clinical research is excluded from this license.

 

		7.	Payments

 

7.1             
Execution and Milestone Payments.

 

(a)               
Within [*] business days of execution of the Agreement, Zomedica shall make payments to Celsee as follows:

 

(i)                
A lump-sum one-time cash payment of $250,000 in consideration of Celsee’s efforts toward [*]

 

(ii)              
A second lump-sum one-time cash payment of $250,000 to assist Celsee in [*]

 

(iii)            
A lump-sum one-time payment of $250,000, with such payment to be in the form of common shares in Zomedica. The number of
common shares to be issued to Celsee shall be determined by the following formula: number of common shares = $250,000/volume-weighted
average price of Zomedica stock over the previous 10 days. This price shall be measured on the NYSE American exchange.

 

    
	 	16	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

(b)              
In addition, Zomedica will pay to Celsee the following amounts upon achievement of the following milestones:

 

(i)                
Upon completion of product development [*] as determined by Zomedica in its sole discretion, Zomedica will (x) make a one-time
payment of $250,000 to Celsee, with such payment to be in the form of common shares in Zomedica. The number of common shares to
be issued will be determined in accordance with the formula in Section 8.1(a)(iii) above and (y) make an additional one-time payment
of $250,000 in cash to Celsee. The payments hereunder shall be made within [*] days of the date of completion of the payment milestone.

 

(ii)              
Upon successful completion of the transfer by Celsee to a streamlined manufacturing process [*] for the Collaboration Product
as determined by Zomedica in its sole discretion, Zomedica will (x) make a one time payment of $250,000 to Celsee, with such
payment to be in the form of common shares in Zomedica. The number of common shares to be issued will be determined in accordance
with the formula in Section 8.1(a)(iii) above and (y) an additional one time payment of $250,000 in cash to Celsee upon achievement
of this milestone. The payments hereunder shall be made within ten (10) days of the date of completion of the payment milestone.

 

7.2             
Registration of Securities.

 

(a)               
The securities to be issued in the agreement have not been registered under the Securities
Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with
the Securities and Exchange Commission or an applicable exemption from such registration requirements. Notwithstanding the foregoing,
the Company shall file a registration statement to register securities from this agreement for resale in the United States, including
the shares of common stock issuable upon achievement of certain milestones, in the time and manner as set forth in Schedule
F attached hereto and incorporated herein by this reference and perform certain other covenants as set forth in such Schedule
F.

 

7.3             
Change of Control.

 

(a)               
In the event of Zomedica Change of Control or the acquisition, sale or other assignment of all or substantially all of the
Zomedica business to which the Agreement relates, all achieved milestones and other payments and stock issuance payable under this
Section 7.1 which have not yet been paid shall become immediately due upon the closing of such transaction. For the avoidance of
doubt, any milestones not yet achieved as of the Change of Control will be paid if and only if such milestones are met in accordance
with the terms of this Agreement, provided, (i) the surviving entity in the Change of Control assumes all obligations of Zomedica
under this Agreement and (ii) if Zomedica no longer exists as a public traded company following such Change of Control, all payments
otherwise payable in the form of Zomedica common stock shall instead be paid to Celsee in U.S. dollars.

 

    
	 	17	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

7.4             
Payments for Supply

 

(a)               
Supply Prices (all figures subject to adjustments, if any, as defined in the Agreement)

 

(i)                
Celsee CTC Platform Technology shall be supplied to Zomedica at a [*] markup over Celsee’s Cost to Manufacture.

 

(ii)              
Celsee Immunochemistry Consumable Packages shall be supplied to Zomedica according to the following schedule:

 

(A)            
Beginning on the date of execution of the Agreement, all Celsee Immunochemistry Consumable Packages shall be supplied at
a per-package price equating to a [*] markup per test over Celsee’s Cost to Manufacture;

 

(B)             
Beginning in the first quarter after Celsee has established a Cost to Manufacture for the Celsee Immunochemistry Package
equating to [*] per test or below, according to the accounting to be provided in Section 8.2(a), all Celsee Immunochemistry Consumable
Packages shall be supplied at a per-package price equating to a [*] markup per test over Celsee’s Cost to Manufacture;

 

(C)             
Beginning in the first quarter after Celsee has established a Cost to Manufacture of [*] per test or below according to
the accounting to be provided in Section 8.2(a), all Celsee Immunochemistry Consumable Package shall be supplied at a per-package
price equating to a [*] markup per test over Celsee’s Cost to Manufacture.

 

(D)            
Cost of Manufacture. Celsee shall provide an accounting of its Cost to Manufacture for the CTC Platform Technology
and Celsee Immunochemistry Consumable Package at the beginning of each Calendar Quarter, which accounting shall be used in the
calculation of the supply pricing for that quarter. Such accounting shall be adjusted to reflect actual Cost to Manufacture at
the end of each calendar quarter for purposes of Collaboration Product pricing for the next succeeding quarter.

 

Records and Audits.
Celsee shall keep (and shall cause its Affiliates and sublicensees and subcontractors to keep) complete and accurate books and
records of accounting pertaining to the amounts due and payable and or any applicable costs and expenses hereunder, including the
Cost of Manufacture in sufficient detail to permit Zomedica to confirm accuracy of all payments due hereunder. For the seven (7)
years following the later of (a) the termination of this Agreement in accordance with its terms and (b) the completion of the Development
Plan, such books and records of accounting shall be kept at each of their principal place of business and no more than once per
Calendar Year (unless Zomedica is required to respond to or by a Government

 

    
	 	18	 
	 	Confidential	 

     

    

Authority) will be open
for inspection during normal business hours and upon prior written notice by an independent certified accountant selected by Zomedica
at Zomedica’s expense, and which is reasonably acceptable to Celsee, for inspecting the Cost of Manufacture and expenditure
under the payments made by Zomedica under this Agreement. Such accountant shall have executed and delivered to Celsee, a customary
confidentiality agreement as reasonably requested by Celsee. The results of such inspection, if any, will be shared by the accountant
with Zomedica and Celsee at either of Celsee’s or Zomedica’s request, and are binding on both Zomedica and Celsee.
If errors of 5% or more in Zomedica’s favor are discovered as a result of such audit, Celsee shall reimburse Zomedica for
the expense of such audit and pay the deficiency together with interest on past due amounts at the Contract Interest Rate per annum
immediately.

 

7.5             
Currency Used and Exchange Rates. All currency amounts in this Agreement are expressed in US Dollars and all payments
to be made by Zomedica to Celsee under this Agreement shall be made in US Dollars by wire transfer in immediately available funds
to a bank and account designated Celsee herein. When conversion of amounts received by Zomedica in any currency other than Dollars
is required, such conversion shall be calculated using the rate of exchange using the following methodology:

 

(a)               
Calculations of sales and costs required by this Agreement will be made in United States Dollars regardless of the countries
in which these sales or costs occur. Net Sales or Costs of Manufacture made in currencies other than Dollars will be converted
into Dollars using a fixed exchange rate (subject to periodic adjustments as described below).

 

(b)              
Exchange rates for all payments under this Agreement will be fixed as of September 30th for a period of twelve (12) months
forward, which is to commence the first business day of the next Calendar Year. The exchange rates will be fixed based on the close
price exchange rates published in the Wall Street Journal for September 30th, where “close price” refers
to the United States dollar/foreign currency exchange rates as published by the Wall Street Journal for September 30th (or the
next business day if rates for September 30th are unavailable) of a given year.

 

(c)               
Exchange rates will reset annually based again on the applicable close price exchange rates. The reset exchange rates shall
apply to all payments based on Net Sales after the reset date for the next twelve-month period and in no event shall such reset
exchange rates be applicable to payments based on Net Sales in prior periods.

 

7.6             
Taxes.

 

(a)               
Zomedica shall be responsible for collection and remittance of taxes on the sale of Collaboration Products by Zomedica to
its customers. Zomedica will make all payments to Celsee under this Agreement without deduction or withholding for Taxes except
to the extent that any such deduction or withholding is required by Law in effect at the time of payment. The Parties agree to
use commercially reasonable efforts to minimize any withholding or similar Tax imposed upon payments payable under this Agreement
and to consult in good faith before taking any action that is reasonably expected to result in the application of a withholding
or similar Tax imposed upon payments payable under this Agreement.

 

    
	 	19	 
	 	Confidential	 

     

    

(b)              
Any Tax required to be withheld on amounts payable under this Agreement will promptly be paid by Zomedica on behalf of Celsee
to the appropriate governmental authority, and Zomedica will furnish Celsee with proof of payment of such Tax. Any such Tax required
to be withheld will be an expense of and borne by Celsee.

 

(c)               
If Zomedica had a duty to withhold Taxes in connection with any payment it made to Celsee under this Agreement and Zomedica
paid such Taxes (the “Assessed Amount”), then Zomedica will notify in writing it paid such Taxes, which notice
will be a copy of the assessment and proof of payment including any other relevant documentation. Zomedica may offset the Assessed
Amount against the immediately following payments owing to Celsee until such Assessed Amount has been fully satisfied.

 

(i)                
Zomedica and Celsee will cooperate with respect to all documentation required by any taxing authority or reasonably requested
by Zomedica to secure a reduction in the rate of applicable withholding taxes. On the date of execution of this Agreement, Celsee
shall provide any tax forms required to be completed for this transaction, including if applicable deliver to Zomedica an accurate
and complete Internal Revenue Service Form W-8BEN-E certifying that Celsee is entitled to the applicable benefits under the Income
Tax Treaty between Canada and the United States.

 

(ii)              
All payments due to Celsee from Zomedica pursuant to this Agreement shall be paid exclusive of VAT and similar commodity
taxes. To support the zero-rating treatment for VAT purposes of any services, intellectual property rights or intangible personal
property supplied by Celsee to Zomedica herein.

 

7.7             
Manner of Payment. All payments to be made by a Party to another Party hereunder shall be in U.S. dollars by wire
transfer to the relevant bank account detailed below or such other bank account as a Party (as applicable) may designate in writing
from time to time during the Term

 

		8.	Intellectual Property

 

8.1             
Publication. Without limitation of Section 9, neither Party shall publish or disclose any data or other Information
arising from the Development Plan or related to the Collaboration Projects without scientific review and prior written approval
by the other Party, provided that such restrictions shall not apply to the information a Party owns or Controls.

 

8.2             
Ownership of Intellectual Property.

 

Ownership
of Intellectual Property under this agreement shall be determined as follows:

 

(a)               
Each Party shall retain ownership over its Background Intellectual Property.

 

(b)              
All Intellectual Property independently or jointly developed by Celsee or Zomedica that is derived from or was developed
using the Celsee Core Technology or that constitutes an improvement to the Celsee Core Technology will be owned by Celsee; provided
however that any such Intellectual Property shall be subject to and included in the License granted Zomedica hereunder.

 

    
	 	20	 
	 	Confidential	 

     

    

(c)               
All Intellectual Property independently developed by Zomedica on or after the Effective Date, and which is not based on
or derived from the Celsee Core Technology and not encompassed in Section 8.2(b) will be the exclusive property and owned by Zomedica.

 

(d)              
Except as set form in (b) and (c) above, any Intellectual property developed independently by either Party subsequent to
the Effective Date shall be owned by the Party that created such Intellectual Property.

 

(e)               
Any other Intellectual property jointly developed or invented will be jointly owned by Celsee and Zomedica (“Joint
Intellectual Property”). Zomedica shall have fully paid-up, royalty-free, worldwide exclusive rights use any of such Joint
Intellectual Property in the Zomedica Field, and Celsee shall have fully paid-up, royalty-free worldwide exclusive rights to use
any of such Joint Intellectual Property in the Celsee Field.

 

8.3             
Invention Disclosure.

 

Each Party shall promptly
disclose to the other Party all inventions arising from the Development Plan that it and any of its Affiliates or subcontractors
discovers or reduces to practice in performing the activities contemplated in the Development Plan or that relates to a Collaboration
Product, its manufacture, use or sale except that nothing herein shall require disclosure of Celsee Core Technology independent
of the Collaboration Product.

 

8.4             
Prosecution of Patents.

 

(a)               
Subject to 8.4(b) each Party shall be responsible for the Prosecution and Maintenance and costs of all Patent Rights it
owns using counsel chosen by them.

 

(b)              
Consultation. With respect to Celsee Controlled Patent Rights that are licensed to Zomedica, Celsee shall provide
Zomedica with copies of all substantive documents relating to the Prosecution and Maintenance of said Patent Rights if desired
by Zomedica and provide Zomedica with a reasonable opportunity to provide comments related to the prosecution of such Patent Rights.

 

8.5             
Infringement of Third-Party Patent Rights. The Parties shall use reasonable efforts to avoid infringing or misappropriating
any Third Party’s Intellectual Property Rights in conducting any activities under this Agreement. Each Party shall promptly
notify the other in the event it becomes aware of any patent rights controlled by a Third Party that may pertain to any such activities
of the Parties.

 

8.6             
Enforcement of Intellectual Property Rights.

 

(a)               
Notification. If a Party becomes aware of any infringement, threatened infringement, or alleged infringement of either
Party’s Intellectual Property on account of a Third Party’s manufacture, use or sale of a product in the Zomedica Field
in the Territory (in each case, a “Product Infringement”), then such Party shall promptly notify the other Party
in writing of such Product Infringement, including any evidence in such Party’s possession demonstrating such Product Infringement.

 

    
	 	21	 
	 	Confidential	 

     

    

(b)              
Enforcement. During the Term and subject to the remainder of this Section 8.6(b), Zomedica shall have the first right
to initiate, prosecute and control legal proceedings against any person or entity engaged in a Product Infringement, at Zomedica’s
expense. If Zomedica decides not to bring such legal action, or if Zomedica fails to initiate such legal action, Celsee shall have
the right, but not the obligation, to commence a suit or take action to enforce the applicable Intellectual Property rights with
respect to such Product Infringement in the Territory, at its own expense.

 

(c)               
Cooperation. Each Party shall provide to the Party enforcing any rights under Section 8.6(b) reasonable assistance
in such enforcement, including joining such action as a party plaintiff if required by Applicable Law to pursue such action. The
enforcing Party shall keep the other Party reasonably and regularly informed of the status and progress of such enforcement efforts,
and shall reasonably consider the other Party’s comments on any such efforts. The non-enforcing Party shall have the right
to be represented in any action brought under Section 8.6(b) by counsel of its choice and at its own expense. For clarity, as between
the Parties, Celsee shall have the exclusive right to bring and control any legal action in connection with any actual, alleged,
or threatened infringement of its Intellectual Property Rights that is not a Product Infringement and is outside the Zomedica Field
at its own expense as it reasonably determines appropriate.

 

(d)              
Settlement. Without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned
or delayed, neither Party shall settle any claim, suit or action brought under Section 8.6 involving the Intellectual Property
rights of a Party in any manner that (i) admits the invalidity of, or otherwise impairs the other Party’s Intellectual
Property or (ii) limits, or would reasonably be expected to limit, the ability of the other Party or its licensees to sell
or manufacture Collaboration Products in the Zomedica Field in the Territory or other products outside the Zomedica Field.

 

(e)               
Recoveries. Any recoveries resulting from an action brought by a Party under Section 8.6(b) relating to a claim of
Product Infringement of an Intellectual Property right hereunder shall be first applied against payment of each Party’s costs
and expenses in connection therewith. Any such recoveries in excess of such costs and expenses (the “Remainder”)
will be retained by the enforcing Party.

 

(f)               
Joint Intellectual Property. If a Third Party infringes any Joint Intellectual Property, the Parties shall discuss
such infringement and the Parties shall each have the right, but neither Party shall be obligated, to bring an appropriate suit
or other action under such Joint Intellectual Property against any Person engaged in such infringement. If both Parties agree to
so enforce such Joint Intellectual Property, they shall be jointly responsible for, and share equally, all the costs and expenses
of any suit brought by them and shall equally share all recoveries with respect thereto. If one Party elects not to enforce such
Joint Intellectual Property against such infringement, then the other Party shall have the right, but not the obligation, to take
action to enforce such Joint Intellectual Property against such infringement at its own cost and expense and such other Party may
retain all recoveries with respect thereto.

 

    
	 	22	 
	 	Confidential	 

     

    

8.7             
Cooperation. Each Party shall reasonably cooperate with the other Party in the Prosecution and Maintenance of the
Intellectual Property, including Patent Rights, pursuant to this Agreement. Such cooperation includes promptly executing all documents,
or requiring inventors, subcontractors, employees, former employees (to the extent reasonably available) and consultants and agents
to execute all documents, as reasonable and appropriate, so as to enable the Prosecution and Maintenance or enforcement of any
such Patent Rights in any country.

 

		9.	Confidentiality

 

9.1             
Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing
or required as a condition of sublicense, the Parties agree that the receiving Party will keep confidential and will not publish
or otherwise disclose or use for any purpose other than as provided for in this Agreement any Information furnished to it by the
other Party pursuant to this Agreement (collectively, “Confidential Information”). Further, subject to Authorized
Disclosures of Section 9.2, each Party shall keep the other Party’s Confidential Information confidential until the information
is no longer confidential or an exception below applies. To the extent that Zomedica will be conducting and funding the research
pursuant to the Development Plan including the Clinical Validations and Approval, all information generated thereunder shall be
the Confidential Information of Zomedica. Notwithstanding the foregoing, Confidential Information will not include any information
to the extent that it can be established by written documentation by the receiving Party that such information:

 

(a)               
is obtained or was already known by the receiving Party or its Affiliates as a result of disclosure from a Third Party that
the receiving Party neither knew nor should have known was under an obligation of confidentiality to the disclosing Party with
respect to such information;

 

(b)              
was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving
Party through no act or omission of the receiving Party or its Affiliates in breach of this Agreement;

 

(c)               
became generally available to the public or otherwise part of the public domain after its disclosure and other than through
any act or omission of the receiving Party or its Affiliates in breach of this Agreement; or

 

(d)              
is independently discovered or developed by the receiving Party or its Affiliates (without reference to or use of Confidential
Information of the disclosing Party) as demonstrated by the receiving Party’s documented evidence prepared contemporaneously
with such independent Development or other equally competent evidence.

 

9.2             
Authorized Disclosure. Except as expressly provided otherwise in this Agreement, each Party may use and disclose
Confidential Information of the other Party solely as follows:

 

(a)               
Each Party or its Affiliates each may disclose Confidential Information that it has received hereunder to their Affiliates
and to those of the personnel and subcontractors of them and their Affiliates who have a need to such information in order to carry
out the work under the Development Plan, perform activities under Section 7.4 or allow Zomedica to Develop and commercialize the
Collaboration Product(s) and who are themselves under a duty of confidentiality;

 

    
	 	23	 
	 	Confidential	 

     

    

(b)              
under appropriate confidentiality provisions substantially equivalent to those in this Agreement: (i) in connection with
the performance of its obligations or as reasonably necessary or useful in the exercise of its rights under this Agreement, and
(ii) to the extent it believes such disclosure is reasonably necessary in conducting the activities contemplated under this Agreement;

 

(c)               
to the extent such disclosure is to a Governmental Authority as reasonably necessary in filing or prosecuting patent applications
in accordance with this Agreement, prosecuting or defending litigation in accordance with this Agreement, complying with applicable
governmental regulations with respect to performance under this Agreement, filing regulatory filings, obtaining Regulatory Approval
or fulfilling post-approval regulatory obligations for a Collaboration Product, or otherwise required by Law, provided, however,
that if a Party is required by Law or the rules of any securities exchange or automated quotation system to make any such disclosure
of the other Party’s Confidential Information it will, except where impracticable for necessary disclosures (for example,
in the event of medical emergency), give reasonable advance notice to the other Party of such disclosure requirement and, in the
case of each of the foregoing, will use its reasonable efforts to secure confidential treatment of such Confidential Information
required to be disclosed;

 

(d)              
to advisors (including to its directors, managers, members, officers, employees, attorneys, accountants, bankers, financial
advisors, subcontractors or consultants) or funding agencies (including that of any Government), to potential investors, financers,
licensees/licensors, partners, collaborators, and parties involved in any other business transactions, including any mergers and
acquisitions, who themselves would be under a duty of confidentiality or as may otherwise be required under applicable Law including
any security laws, under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent
to those of this Agreement; or

 

(e)               
to the extent mutually agreed to by the Parties.

 

9.3             
Confidential Treatment of Terms and Conditions. Subject to the exceptions set out in Section 9.2, neither Party shall
disclose the terms and conditions of this Agreement except as may be required by Law or as necessary to effect terms of this Agreement.

 

9.4             
Attorney-Client Privilege. Neither Party is waiving, nor will be deemed to have waived or diminished, any of its
attorney work product protections, attorney-client privileges or similar protections and privileges as a result of disclosing information
pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened
litigation) to the receiving Party, regardless of whether the disclosing Party has asserted, or is or may be entitled to assert,
such privileges and protections. The Parties:

 

(a)               
share a common legal and commercial interest in such disclosure that is subject to such privileges and protections;

 

    
	 	24	 
	 	Confidential	 

     

    

(b)              
may become joint defendants in proceedings to which the information covered by such protections and privileges relates;

 

(c)               
intend that such privileges and protections remain intact should either Party become subject to any actual or threatened
proceeding to which the disclosing Party’s Confidential Information covered by such protections and privileges relates; and

 

(d)              
intend that after the Effective Date both the receiving Party and the disclosing Party will have the right to assert such
protections and privileges.

 

		10.	Representations, Warranties and Covenants

 

10.1         
Mutual Representations and Warranties. In addition to the representations and warranties made by a Party elsewhere
in this Agreement, each Party hereby represents and warrants to the other Party that:

 

(a)               
 it is duly organized and validly existing under the Laws of its jurisdiction of organization and it has full corporate
power and authority and has taken all corporate action necessary to enter into and perform this Agreement;

 

(b)              
It has duly executed and delivered this Agreement and this Agreement is a legal and valid and binding obligation upon such
Party and enforceable in accordance with its terms subject only to bankruptcy, insolvency, liquidation, reorganization, moratorium
and other similar laws generally affecting the enforcement of creditors’ rights and to the fact that equitable remedies,
such as specific performance and injunction, are discretionary remedies;

 

(c)               
the execution, delivery and performance of the Agreement by such Party does not (i) conflict with any agreement, instrument
or understanding, oral or written, by which it is bound, including its organizational documents (ii) conflict with, violate
or constitute a default or require any consent under any contractual obligation or court or administrative order by which such
Party is bound or (iii) to its knowledge violate any Law; and the person or persons executing this Agreement on such Party’s
behalf have been duly authorized to do so by all requisite corporate action;

 

(d)              
it has sufficient legal right and/or beneficial title or ownership of its respective Intellectual Property (including Controlled
Technology) to grant the licenses to the other Party as purported to be granted pursuant to this Agreement;

 

(e)               
there is no action, litigation or other proceeding in progress, pending or, to its knowledge threatened against it which
might result in a material adverse change in its financial condition or which would materially adversely affect its ability to
perform its obligations under this Agreement.

 

(f)               
All representations and warranties of the Parties will be correct as of the Effective Date and deemed to be continuously
given throughout the Term. To the extent a Party becomes aware that any of the representations and warranties are no longer valid
as of a date post- the Effective Date, it shall immediately notify the other Party of same.

 

    
	 	25	 
	 	Confidential	 

     

    

10.2         
Celsee Representations, Warranties and Covenants. In addition to the representations and warranties made by Celsee
above and elsewhere in this Agreement, Celsee hereby represents, warrants, and covenants to Zomedica that:

 

(a)               
As of the Effective Date, it has, or will have during the Term of this Agreement, the full right, power and authority to
grant to Zomedica the licenses hereunder granted in this Agreement;

 

(b)              
As of the Effective Date, there is no suit or legal proceeding pending or threatened in writing with respect to the Background
Intellectual Property and it is has no actual knowledge or notice of any infringement of Third Party Intellectual Property by it
that would arise in conducting the activities contemplated by this Agreement; All Patents that have issued are valid and enforceable.

 

(c)               
As of the Effective Date, Celsee has not entered, and during the Term, will not enter, into any written agreement with a
Third Party that conflicts with the rights granted to Zomedica hereunder or Celsee’s ability to fully perform its obligations
hereunder;

 

(d)              
Celsee has not entered into any written agreement with a Third Party to conduct research with respect to the Celsee Controlled
Technology in the Zomedica Field and Celsee is not collaborating with any Third Parties for the Development of Products in the
Zomedica Field;

 

(e)               
Subject to Section 10.2(d), as of the Effective Date, Celsee has not granted any rights to Third Parties to the Celsee Controlled
Technology in the Zomedica Field or the Collaboration Product(s);

 

(f)               
Neither Celsee nor any of its Affiliates has been disbarred or is subject to debarment and neither Celsee nor any of its
Affiliates shall use in any capacity in connection with the services to be performed under this agreement any person who has been
debarred pursuant to Section 306 of the Food Drug and Cosmetic Act (21 U.S.C. 335a) (the “Act”) or who is
subject of a conviction described in such section. Celsee agrees to inform Zomedica in writing immediately if any person who is
performing services on behalf of Celsee under this Agreement is debarred or is the subject of a conviction described in Section
306 of the Act or if any action, suit, claim, investigation or legal or administrative proceeding or to the knowledge of Celsee
is threatened relating to the debarment or conviction of Celsee or any person performing services on behalf of Celsee under this
Agreement.

 

(g)              
Schedule B accurately lists all Celsee Controlled Patent Rights as of the Effective Date;

 

(h)              
That its representatives contributing and conducting activities under this Agreement on behalf of Celsee, including with
respect to the Development Plan, all have assigned and have a duty to assign their rights and contributions with respect to any
Technology or Intellectual Property developed pursuant to this agreement to Celsee and to no other party;

 

(i)                
That it has or will have the ability to and shall manufacture and supply the Collaboration Product(s), the Celsee Platform
Technology and the CTC Consumable Packages in accordance with Laws (subject to Zomedica obtaining required regulatory approvals)
and volumes forecasted pursuant to this Agreement and has sufficient contingency plans in place to so manufacture and supply.

 

    
	 	26	 
	 	Confidential	 

     

    

10.3         
Disclaimer of Warranties. EXCEPT AS OTHERWISE SET FORTH IN ARTICLE 10 OF THIS AGREEMENT, THE PARTIES EXPRESSLY DISCLAIM
ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE PATENT RIGHTS, INFORMATION
AND ANY OTHER SUBJECT MATTER RELATING TO THIS AGREEMENT, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
VALIDITY OR NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS.

 

		11.	Limitations of Liability; Insurance

 

11.1         
Limitations of Liability. IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, INCIDENTAL,
EXEMPLARY, MULTIPLE, CONSEQUENTIAL, OR PUNITIVE DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, OR FOR
ANY LOSS OR INJURY TO A PARTY’S PROFITS OR GOODWILL, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT,
TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), EVEN IF SUCH PARTY WAS ADVISED OR OTHERWISE AWARE OF THE LIKELIHOOD
OF SUCH DAMAGES, EXCEPT WITH RESPECT TO CONSEQUENTIAL DAMAGES (WHICH IN NO EVENT WILL INCLUDE ANY PUNITIVE DAMAGES) AWARDED TO
A PARTY THAT THE NON-BREACHING PARTY DEMONSTRATES RESULTED FROM A BREACH OF SECTION 9.1 (CONFIDENTIALITY; EXCEPTIONS), OR SECTION
9.2 (AUTHORIZED DISCLOSURE). NOTHING IN THIS SECTION 11.1 (LIMITATIONS OF LIABILITY) IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER ARTICLE 12 (INDEMNIFICATION) WITH RESPECT TO ANY DAMAGES PAID BY THE OTHER PARTY TO
A THIRD PARTY IN CONNECTION WITH A THIRD PARTY CLAIM.

 

11.2         
Insurance. Each Party shall procure and maintain insurance, including product liability insurance, with respect
to its activities hereunder and which are consistent with normal business practices of prudent companies similarly situated at
all times during which any Collaboration Product is being clinically tested in animals or commercially distributed or sold. Each
Party represents and warrants to the other Party that it has such insurance in effect as of the Effective Date and if requested
by the other Party will provide the other Party a copy of the certificate of insurance evidencing such insurance on or prior to
the Effective Date. It is understood that such insurance shall not be construed to create a limit of either Party’s liability
with respect to its indemnification obligations under Article 12. Each Party shall provide the other with written notice at least
thirty (30) days prior to the cancellation, non-renewal or material change in such insurance or self-insurance which materially
adversely affects the rights of the other Party hereunder.

 

    
	 	27	 
	 	Confidential	 

     

    

		12.	Indemnification

 

12.1         
Indemnification by Celsee. Celsee hereby agrees to defend, hold harmless and indemnify (collectively, “Indemnify”)
Zomedica and its Affiliates, and its and their directors, officers, employees, contractors and agents (collectively, the “Zomedica
Indemnitees”) from and against any liability or expense (including reasonable legal expenses, costs of litigation and
attorneys’ fees), damages, or judgments, whether for money or equitable relief (collectively, “Losses”)
resulting from suits, proceedings, claims, actions, demands, or threatened claims, actions or demands, in each case brought by
a Third Party (each, a “Third Party Claim”) against a Zomedica Indemnitee, including, for each of clauses (a),
(b) and (c), below, bodily injury, risk of bodily injury, death (including death of a Companion Animal), property damage, and product
liability Third Party Claims or the failure to comply with Law arising out of or relating to, directly or indirectly:

 

(a)               
Celsee’s, its Affiliates or subcontractors’ (collectively, the “Celsee Parties”) activities,
including Development activities, under the Development Plan and the manufacture, supply, transfer, labeling, handling or storage
of the Collaboration Product;

 

(b)              
the Celsee Parties’ negligence, recklessness, intentional misconduct or intentional acts or omissions; provided that
the foregoing shall not apply to any action or omission undertaken at the direction or request of any Zomedica Indemnitee outside
of the Development Plan; or

 

(c)               
Celsee’s material breach of any duty, representation, warranty, obligation or covenant set out in this Agreement;

 

(d)              
Celsee’s failure to supply Collaboration Product in accordance with forecasted volumes agreed to by the parties;

 

(e)               
Celsee’s obligation to Indemnify the Zomedica Indemnitees pursuant to this Section 12.1 shall not apply to the extent
that any such Losses (i) arise from the acts or omissions of any Zomedica Indemnitee; (ii) arise from any material breach
by Zomedica of this Agreement; or (iii) arising out of Zomedica’s activities under the Development Plan.

 

12.2         
Indemnification by Zomedica. Zomedica hereby agrees to Indemnify Celsee and its Affiliates, and its and their directors,
officers, employees, contractors and agents (the “Celsee Indemnitees”) from and against any and all Losses resulting
from Third Party Claims, including, for each of clauses (a), (b) and (c), below, bodily injury, risk of bodily injury, death, property
damage, and product liability Third Party Claims or the failure to comply with Law arising out of or relating to, directly or indirectly:

 

(a)               
Zomedica’s, its Affiliates’, sublicensees’, wholesalers’, distributors’ or sub-contractors’
(collectively, the “Zomedica Parties”) activities (including Development) under the Development Plan, use, Development,
commercialization, transfer, labeling, handling or storage, promotion, marketing, distribution, offer for sale, sale, import or
export of any Collaboration Product in the Territory;

 

    
	 	28	 
	 	Confidential	 

     

    

(b)              
the Zomedica Parties’ negligence, recklessness, intentional misconduct or intentional acts or omissions; provided
that the foregoing shall not apply to any action or omission undertaken at the direction or request of any Celsee Indemnitee outside
of the Development Plan; or

 

(c)               
Zomedica’s material breach of any duty, representation, warranty or covenant set out in this Agreement.

 

(d)              
Zomedica’s obligation to Indemnify the Celsee Indemnitees pursuant to the foregoing sentence shall not apply to the
extent that any such Losses (i) arise from the acts or omissions of any Celsee Indemnitee; (ii) arise from any material
breach by Celsee of this Agreement; or (iii) arising out of Celsee’s activities under the Development Plan.

 

12.3         
Claim for Indemnification. Whenever any Claim or Loss arises for which a Zomedica Indemnitee or a Celsee Indemnitee
(the “Indemnified Party”) may seek indemnification under this Article 12 (Indemnification), the Indemnified
Party will promptly notify the other Party (the “Indemnifying Party”) of the Claim or Loss and, when known,
the facts constituting the basis for the Claim or Loss; provided, however, that the failure by an Indemnified Party to give such
notice or to otherwise meet its obligations under this Section 12.3 (Claim for Indemnification) does not relieve the Indemnifying
Party of its indemnification obligation under this Agreement except and only to the extent that the Indemnifying Party is actually
prejudiced as a result of such failure. The Indemnifying Party has exclusive control of the defense and settlement of all Claims
for which it is responsible for indemnification and shall assume the defense thereof at its own expense promptly upon notice of
such Claim or Loss. The Indemnified Party shall not settle or compromise any Claim by a Third Party for which it is entitled to
indemnification without the prior written consent of the Indemnifying Party, unless the Indemnifying Party is in breach of its
obligation to defend hereunder. In no event can the Indemnifying Party settle any Claim without the prior written consent of the
Indemnified Party if such settlement does not include a complete release from liability on such Claim or if such settlement would
involve undertaking an obligation other than the payment of money, would bind or impair the Indemnified Party, or includes any
admission of wrongdoing or that any intellectual property or proprietary right of the Indemnified Party is invalid or unenforceable.
The Indemnified Party shall reasonably cooperate with the Indemnifying Party at the Indemnifying Party’s expense and shall
make available to the Indemnifying Party reasonably requested information under the control of the Indemnified Party, which information
is subject to Article 9 (Confidentiality). The Indemnifying Party shall permit the Indemnified Party to participate in (but not
to control) the Third Party Claim through counsel of its choosing (to the extent it has the ability to do so). Notwithstanding
any other provision of this subsection, if an Indemnified Party withholds consent to a bona fide settlement offer, where but for
such action, the Indemnifying Party could have settled such Claim, the Indemnifying Party shall be required to indemnify the Indemnified
Party only up to a maximum of the bona fide settlement offer for which the Indemnifying Party could have settled such Claim.

 

    
	 	29	 
	 	Confidential	 

     

    

[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

12.4         
Limitation of Indemnification. Celsee’s liability for indemnification pursuant to Section 12.1, and Zomedica’s
liability for indemnification pursuant to Section 12.2 herein, shall be limited in total and in the aggregate to an amount equal
to [*].

 

		13.	Term and Termination

 

13.1         
Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the
terms hereof shall extend for seven (7) years (the “Initial Term”) and automatically renewal for additional one-year
terms (such time period collectively referred to as the “Term”).

 

13.2         
Termination by both Parties.

 

(a)               
Either Party may terminate this Agreement upon written notice to the other Party:

 

(i)                
Material Breach. By the non-breaching party in the event of any material breach by a Party of this Agreement; provided
that the non-breaching Party provides notice of such breach to the other Party specifying the nature of the alleged breach and
such breach has not been cured by the breaching Party within thirty (30) days after such notice thereof; and/or

 

(ii)              
Mutual Consent. By mutual written consent of the Parties.

 

13.3         
Termination for Insolvency or Bankruptcy.

 

(a)               
Insolvency Event; Definition. Either Party may terminate this Agreement in its entirety upon providing written notice
to the other Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files an
insolvency petition in bankruptcy or makes a voluntary assignment in bankruptcy, petitions, applies for or acquiesces to the appointment
of any receiver, receiver and manager, interim receiver, trustee or similar officer or official to liquidate or conserve its business
or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy,
reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of or other relief
for financially distressed debtors, or becomes a party to any proceeding or action of the type described above and not dismissed
within ninety (90) days of filing or released within ninety (90) days of the event(each, an “Insolvency Event”).

 

(b)              
Bankruptcy Laws.

 

(i)                
All rights and licenses granted to Zomedica under or pursuant to this Agreement, including, for the avoidance of doubt,
the licenses granted to Zomedica pursuant to this Agreement, are, and shall otherwise be deemed to be, for purposes of Section
32(6) of the Companies’ Creditors Arrangement Act (Canada) (“CCAA”), Section 65.11(7) of the Bankruptcy
and Insolvency Act (Canada) (“BIA”) or for purposes of Section 365(n) of the U.S. Bankruptcy Code, if applicable,
and other similar laws in any jurisdiction outside of Canada (collectively, the “Bankruptcy Laws”), licenses
of rights to “intellectual property” as contemplated under the Bankruptcy Laws including, licenses of right to “intellectual
property” as defined under Section 101 of the U.S. Bankruptcy Code.

 

    
	 	30	 
	 	Confidential	 

     

    

(ii)              
Upon the occurrence of any Insolvency Event with respect to Celsee (the “Insolvent Party”), Celsee agrees
that Zomedica, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections
under the Bankruptcy Laws.

 

(iii)            
Further, it is the intention of the Parties that if either party becomes insolvent, the other party shall have an exclusive
option, exercisable upon written notice to the other party, to negotiate a paid-up license to any intellectual property necessary
to independently continue commercialization of the Collaboration Product(s), including the Celsee CTC Platform Technology and Celsee
Immunochemistry Consumable Package(s) in the Zomedica Field.

 

(iv)            
Further, each Party agrees and acknowledges that all payments hereunder, other than the milestone payments pursuant to Section
7.1 do not constitute “obligations owing under the agreement in relation to the use of the intellectual property” as
contemplated by Section 32(6) of the CCAA or Section 65.11(7) of the BIA or 365 (n)(2)(B) of the US Bankruptcy Code or relate
to licenses of intellectual property hereunder.

 

(v)              
Each Party shall, during the term of this Agreement, create and maintain current copies or, if not amenable to copying,
detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property.

 

(vi)            
Each Party agrees and acknowledges that “intellectual property” as contemplated by the Bankruptcy Laws include
laboratory notebooks, cell lines, product samples and inventory, research studies and data, regulatory approvals and regulatory
materials in each case to the extent related to the Collaboration Products.

 

(vii)          
It is the intention of the parties that if:

 

(A)            
a case or proceeding is commenced during the Term by or against Celsee under the Bankruptcy Laws;

 

(B)             
this Agreement is disclaimed as provided for under the Bankruptcy Laws; and

 

(C)             
Zomedica elects to retain its rights hereunder as provided for under the Bankruptcy Laws or otherwise,

 

then Celsee
(in any capacity) and its successors and assigns (including a receiver, interim receiver or trustee in bankruptcy and any assignee
thereof of any right or power of attorney that Celsee may have or may exercise under, or in connection with, this Agreement), shall
(i) provide to Zomedica immediately upon Zomedica’s written request copies of all such intellectual property (including embodiments
thereof) held by Celsee and such successors and assigns, or otherwise available to them, and (ii) not interfere with Zomedica’s
rights under this Agreement, or any related agreements between the Parties, to such intellectual property (including such embodiments),
including any right to obtain such intellectual property (or such embodiments) from another entity.

 

    
	 	31	 
	 	Confidential	 

     

    

(viii)        
Whenever Celsee or any of its successors or assigns provides to Zomedica any of the intellectual property licensed hereunder
(or any embodiment thereof) pursuant to this Section 13.3, Zomedica shall have the right to perform Celsee’s obligations
hereunder with respect to such intellectual property, but neither such provision nor such performance by Zomedica shall release
Celsee from liability resulting from disclaimer of the license or the failure to perform such obligations.

 

(ix)            
All rights, powers and remedies of Zomedica as provided herein are in addition to and not in substitution for any and all
other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of
the commencement of a case or proceeding by or against Celsee under the Bankruptcy Laws.

 

(x)              
In particular, it is the intention and understanding of the Parties that the rights granted to Zomedica under this Section
13.3 are essential to the Parties’ respective businesses and the Parties acknowledge that damages are not an adequate remedy.

 

(xi)            
The Parties agree that they intend the following rights to extend to the maximum extent permitted by applicable Law, and
to be enforceable under Section 32(6) of the CCAA and Section 65.11(7) of the BIA and the relevant provisions of the US Bankruptcy
Code:

 

(A)            
the right of access to any intellectual property (including embodiments thereof) of Celsee, or any Third Party with whom
Celsee contracts to perform an obligation of Celsee under this Agreement, and, in the case of the Third Party, which is necessary
for the exploitation of Collaboration Products;

 

(B)             
the right to contract directly with any Third Party to complete the contracted work upon failure of Celsee to comply with
its applicable obligations; and

 

(C)             
in favor of Zomedica, the right to the benefit of the exercise of any power of attorney held by Celsee to grant to Zomedica
the rights and licenses provided in this Agreement.

 

Further, it
is the intention of the Parties that this Agreement, even if not disclaimed, be binding on any party that purchases the intellectual
property licensed to Zomedica, or any power of attorney that permits such license to Zomedica, pursuant to any Bankruptcy

 

    
	 	32	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

Laws, notwithstanding
any approval and vesting order that may be issued in respect of such intellectual property or power and that Zomedica receive reasonable
prior notice of any motion brought pursuant to any Bankruptcy Laws to approve such sale. For greater certainty, nothing herein
shall be construed as a waiver of any right that Zomedica may have to object to such sale, including on the basis that such sale
of intellectual property or power is contrary to the terms of this Agreement.

 

13.4         
Effect of Termination or Expiration.

 

(a)               
Prior to Clinical Validation. Prior to Clinical Validation, upon the effective date of termination or expiration
of the Term, except as otherwise expressly provided herein, all rights and obligations of each Party with respect to the whole
Agreement or to those Collaboration Products which are the subject of the termination shall cease, including all rights and licenses
granted by a Party to the other Party with respect to same. Each Party shall return to the other their respective Confidential
Information and Controlled Intellectual Property and Materials (provided that each Party may keep one copy of such Confidential
Information for archival purposes only).

 

(b)              
The Parties shall use Commercially Reasonable Efforts and cooperate to diligently wind down, according to good clinical
and industry practice, any clinical trials that are ongoing for Collaboration Product(s) in the Territory at the time of notice
of such termination and to assure a smooth termination transition with respect to the Collaboration Product trials being conducted
by or on behalf of Zomedica (or its Affiliate or sublicensee) at the time of notice of termination which Zomedica determines to
continue in compliance with the Laws and ethical guidelines applicable to the transfer or termination of such studies and commercial
activities, if any, provided that nothing herein shall require Zomedica to undertake any new Development, manufacture or commercialization
or other activities.

 

(c)               
Upon termination of this Agreement, the parties shall pay each other the entire amount of any financial commitments incurred
by a Party prior to termination even if those financial commitments come due after termination in accordance with the Development
Plan Budget that exceed amounts paid by the owing party to the other party hereunder prior to such termination and cannot be canceled;
except that the owing party shall only be responsible for paying [*]. Upon receipt of notice of termination, to the extent possible,
the parties shall promptly terminate any outstanding commitments and avoid incurring any further costs under the Development Plan.
No later than [*] after the effective date of termination or expiration of the Term, unless another period is agreed to in writing
by the Parties, the Party may provide an invoice to the other Party in respect of the final payment due and payable. The owing
Party shall pay all such amounts no later than [*] after receipt of such invoice. Notwithstanding the foregoing, it is understood
that, in no event shall the funds payable exceed the maximum amount set forth in the Development Plan Budget or any supply order.
In addition, within [*] after such effective date of termination each Party shall provide the other with a final accounting for
all Development Plan Budget and supply orders. Should the final accounting indicate an amount is due to a Party, such final payment
will be made in accordance with Section 7.1. If the final accounting indicates an overpayment the party which received the overpayment
shall refund such overpayment to the other Party within [*] of the final accounting.

 

    
	 	33	 
	 	Confidential	 

     

    

[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

(d)              
Accrued Rights. Expiration or termination of this Agreement (or any provision hereof) for any reason is without
prejudice to any right that shall have accrued to the benefit of a Party prior to such expiration or termination, including damages
arising from any breach under this Agreement. Expiration or termination of this Agreement does not relieve a Party from any obligation
that is expressly indicated to survive such expiration or termination.

 

13.5         
Non-Exclusive Distribution Rights for the Post-Term Period.

 

(a)               
Notwithstanding anything to the contrary, in the event of any expiration or termination of this Agreement, other than termination
by Celsee for Zomedica’s uncured material breach under Section 13(a)(i), termination by mutual agreement under 13(a)(ii)
or termination prior to Clinical Validation under 13.4(a), and provided that Zomedica has made all required payments under Section
7.1 and has issued all stock to be issued under Section 7.2: (A) Zomedica may continue to distribute, market and promote sales
of the CTC Consumable Package for use in the Zomedica Field in the Territory on a non-exclusive basis for a period of [*] from
the effective date of such expiration or termination (the “Post Term Period”), and (B) Celsee will continue to supply
the CTC Consumable Package products to Zomedica during the Post Term Period at the pricing set forth in this Agreement; in each
case, subject to the terms and conditions of this Section 13.5. Notwithstanding the foregoing, if Zomedica fails to purchase CTC
Consumable Package Products during the Post Term Period for [*], all licenses and rights to purchase CTC Consumable Package Products
during the Post Term Period shall immediately terminate. Subject to the foregoing, all provisions of this Agreement will continue
to apply during the Post Term Period, with the following exceptions:

 

(i)                
the license granted to Zomedica pursuant to Section 6.2 shall automatically convert to non-exclusive during the Post Term
Period;

 

(ii)              
Section 2.8 (“Exclusivity”) shall not apply during the Post Term Period;

 

(iii)            
the rights granted to Zomedica pursuant to Section 4.2(a) (“Manufacturing and Product Supply”) shall automatically
convert to non-exclusive during the Post Term Period;

 

(iv)            
Section 13.3(b) (“Bankruptcy License Option”) shall not apply during the Post Term Period.

 

13.6         
Survival. The following provisions shall survive termination or expiration of this Agreement: Sections 7, 8, , 9,
10, 11, 12, 13.4,, 14 and 15 and Section 1 to the extent necessary to give effect to the foregoing. In addition, except as provided
in Section 13.5, all other provisions of this Agreement shall survive the expiration or termination of this Agreement until the
end of the Post Term Period.

 

    
	 	34	 
	 	Confidential	 

     

    

		14.	Dispute Resolution

 

14.1         
Discussion by Senior Executives. If there is an unresolved matter, dispute or issue arising out of or relating to
the existence, negotiation, validity, formation, interpretation, breach, performance or application of this Agreement (each, a
“Dispute”) for which neither Party has the final decision making authority as expressly provided elsewhere in this
Agreement, either Party will refer such Dispute to their respective Presidents (such persons, the “Senior Executives”),
or their designee(s), in writing for further discussion and resolution. These individuals shall as soon as practicable meet and
attempt in good faith to resolve the Dispute and reach agreement. These individuals may obtain the advice of other employees or
consultants as they deem necessary or advisable in order to make the decision. If these individuals cannot reach agreement as to
the Dispute within thirty (30) days of the Dispute being referred to them, then such Dispute will be resolved as set out in this
Article 14.

 

14.2         
Mediation and Arbitration. If the Senior Executives are not able to resolve such Dispute referred to them
under Section 14.1 within thirty (30) days, the Parties shall first refer such Dispute to proceedings under the International
Chamber of Commerce (“ICC”) Mediation Rules. If the dispute has not been settled pursuant to the said Rules within
forty-five (45) days following the filing of a Request for Mediation or within such other period as the parties may agree in writing,
such dispute shall thereafter be finally settled under the Rules of Arbitration of the International Chamber of Commerce by one
or more arbitrators appointed in accordance with the said Rules of Arbitration. Except to the extent necessary to confirm an award
or as may be required by law, neither Party nor any arbitrator may disclose the existence, content, or results of an arbitration
without the prior written consent of both parties.

 

14.3         
Patent Dispute Resolution. Any Dispute relating to the ownership, scope, validity, enforceability or infringement
of any Patent Rights shall be submitted to a court of competent jurisdiction in which such Patent Rights exist.

 

14.4         
Payment Dispute Resolution. Notwithstanding the provisions of Section 14.2, any dispute, controversy or claim relating
to the calculation of Cost of Manufacture or a payment made pursuant to this Agreement shall be submitted for resolution to a member
(the “Arbitrator”) of an accounting firm of national standing selected by both Parties (and which shall not
be the auditor of either of the Parties) within thirty (30) days after notice of the dispute is received or deemed to be received
by a Party. If the Parties cannot agree on an Arbitrator, the provisions of Section 14.2 shall apply. The Parties shall make submissions
to the Arbitrator within ninety (90) days after the selection of the Arbitrator and the Arbitrator will select one Party’s
submission. If the Parties cannot agree on a member of the accounting firm, the provisions of Section 14.2 shall apply. The decision
of the Arbitrator in selecting on Party’s submission shall be final and binding on both Parties.

 

14.5         
Waiver. EACH PARTY HERETO (1) WAIVES ITS RIGHT TO TRIAL UNDER ANY ISSUE BY JURY WITH RESPECT TO ANY DISPUTE BROUGHT
UNDER THIS AGREEMENT, (2) WITH THE EXCEPTION OF RELIEF MANDATED BY STATUTE, ANY CLAIM TO PUNITIVE, EXEMPLARY, MULTIPLIED, INDIRECT,
CONSEQUENTIAL OR LOST PROFITS/REVENUES DAMAGES, AND (3) ANY CLAIM FOR ATTORNEY FEES, COSTS AND PREJUDGMENT INTEREST.

 

    
	 	35	 
	 	Confidential	 

     

    

		15.	Miscellaneous.

 

15.1         
Affiliates and Designees. Each Party has the right to exercise their respective rights, perform their respective
obligations and/or receive performance of the other Party’s obligations hereunder through their Affiliates or sublicensees.

 

15.2         
Assignment.

 

(a)               
Neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred (whether by operation
of Law, general succession or otherwise) by either Party without the prior written consent of the other Party, said consent not
to be unreasonably withheld.

 

(b)              
The above notwithstanding, either party may, without the other party’s consent, assign such rights: (i) to an Affiliate;
(ii) in connection with the transfer or sale of all or substantially all of the business of such Party to which the Agreement relates
to a third party, whether by merger, sale of stock, sale of assets or otherwise; and (iii) in connection with a Change of Control.

 

(c)               
The rights and obligations of the parties under this Agreement shall be binding upon and enures to the benefit of the Parties
and their respective successors and permitted assigns. The Parties shall promptly notify the other Party of any transfer under
said Section 15.2 or any Change of Control.

 

15.3         
Counterparts. This Agreement may be executed in counterparts with the same effect as if both Parties had signed the
same document. All such counterparts will be deemed an original, will be construed together and will constitute one and the same
instrument. Signature pages of this Agreement may be exchanged by facsimile or other electronic means without affecting the validity
thereof.

 

15.4         
No Contra Proferentem. This Agreement has been reviewed by each Party’s professional advisors, and revised
during the course of negotiations between the Parties. Each Party acknowledges that this Agreement is the product of their joint
efforts, that it expresses their agreement, and that, if there is any ambiguity in any of its provisions, no rule of interpretation
favoring one Party over another based on authorship will apply.

 

15.5         
Entire Agreement. This Agreement, including the attached Schedules constitutes the entire agreement between
the Parties as to the subject matter of this Agreement, and supersedes and merges all prior discussions, representations, agreements
and understandings regarding the same.

 

15.6         
Time is of the Essence. Time is of the essence in all respects of this Agreement.

 

15.7         
Force Majeure. Neither Party is liable for a delay or failure in the performance of any of its obligations hereunder
(other than the payment of money) if such delay or failure is due to causes beyond its reasonable control, including acts of God,
fires, floods, earthquakes, labor strikes, acts of war, terrorism or civil unrest (“Force Majeure”); provided,
however, that the affected Party notifies the other Party in writing within thirty (30) days of the Force Majeure event (and continues
to provide monthly status updates to the other Party for the duration of the effect); further provided that the affected Party
will use its reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence,
and will continue performance with reasonable dispatch whenever such causes are removed.

 

    
	 	36	 
	 	Confidential	 

     

    

15.8         
Further Assurances. Each Party agrees to do and perform all such further acts and things and will execute and deliver
such other agreements, certificates, instruments and documents necessary or that the other Party may reasonably request in order
to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights
hereunder.

 

15.9         
Headings. Headings and captions are for convenience only and are not to be used in the interpretation of this
Agreement.

 

15.10     
Notices. Any notice required or permitted to be given by this Agreement will be in writing, in English, and
will be delivered by hand or overnight courier with tracking capabilities or transmitted by confirmed facsimile, charges (if any)
prepaid and addressed as set forth below unless changed by notice so given:

 

	If to CELSEE:	 	Celsee, Inc.
	 	 	
        46701
        Commerce Center Drive,

        Plymouth,
        MI 48170,

        USA

         

	 	 	
        Attn: Kalyan Handique

        Title: President & COO

	 	 	Facsimile:  
	 	 	 
	If to Zomedica:	 	3928 Varsity Drive
	 	 	Ann Arbor, MI  48108
	 	 	USA
	 	 	Attn:  Jerry Solensky
	 	 	Title:  Chief Executive Officer
	 	 	 
	 	 	Facsimile: (734) 436-8680

E-mail:  jsolensky@zomedica.com

 

Any such notice
will be deemed given or made and received on the date delivered provided that if that day is not a Business Day then the notice
will be deemed to have been given or made and received on the next Business Day. A Party may add, delete (so long as at least one
person is remaining), or change the person or address to which notices should be sent at any time upon written notice delivered
to the other Party in accordance with this Section 15.10 (Notices).

 

15.11     
Relationship of the Parties. Each Party is an independent contractor under this Agreement. Nothing contained herein
is intended or is to be construed so as to constitute Zomedica and Celsee as partners, agents or joint venturers. Neither Party
has any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party
or to bind the other Party to any contract, agreement or undertaking with any Third Party.

 

    
	 	37	 
	 	Confidential	 

     

    

15.12     
Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the
provision will be considered severed from this Agreement and will not serve to invalidate any remaining provisions hereof. The
Parties will negotiate in good faith to replace any invalid or unenforceable provision with a valid and enforceable one such that
the objectives contemplated by the Parties when entering this Agreement may be realized.

 

15.13     
Third Party Beneficiaries. Except as expressly provided with respect to Celsee Indemnitees or Zomedica Indemnitees
in Article 12 (Indemnification) (for whom Celsee and Zomedica, respectively, hold such rights in trust), there are no third-party
beneficiaries intended hereunder and no Third Party will have any right or obligation hereunder.

 

15.14     
Waivers and Modifications. The failure of any Party to insist on the performance of any obligation hereunder is not
be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof is not be deemed to be a waiver of any
other breach of such provision or any other provision on such occasion or any other occasion. No waiver, modification, release
or amendment of any right or obligation under or provision of this Agreement will be valid or effective unless in writing and signed
by all Parties hereto.

 

15.15     
Vienna Convention. The United Nations Convention on Contracts for the International Sale of Goods (also called
the Vienna Convention) will not be applicable to this Agreement or the transactions contemplated by this Agreement.

 

15.16     
Governing Law. This Agreement and any dispute hereunder will be governed by the laws of the state of Delaware and
the federal laws of the United States of America applicable therein. Subject to the provisions of Section 14, the Parties attorn
to the non-exclusive jurisdiction of the courts of Michigan.

 

THE REMAINDER OF THIS PAGE IS INTENTIONALLY
LEFT BLANK

 

    
	 	38	 
	 	Confidential	 

     

    

IN WITNESS WHEREOF, the Parties
have executed this Agreement by proper persons thereunto duly authorized as of the Effective Date set forth above.

 

 

 

	CELSEE, Inc.	 	Zomedica Pharmaceuticals Corp.
	 	 	 	 	 
	By: 	/s/ Kaylan Handique	 	By: 	/s/ Gerald Solensky Jr.
	Title: 	President	 	Title: 	Chairman and CEO
	Date:	December 20, 2017	 	Date:	December 20, 2017

 

 

 

 

 

    
	 	39	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

SCHEDULE
A

COLLABORATION PRODUCT DEVELOPMENT PLAN

 

[*]

 

 

 

 

 

 

 

 

    
	 	40	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

SCHEDULE B

 

CELSEE PATENT RIGHTS

 

[*]

 

 

 

 

 

 

 

    
	 	41	 
	 	Confidential	 

     

    

SCHEDULE C

COMPLIANCE SCHEDULE AND CODE OF CONDUCT

 

Compliance
with Laws including FCPA/CFPOA and HIPAA/PIPEDA

 

		1.1.	Each Party acknowledges that the other Party aims to perform its activities, and to have parties
who enter into business arrangements with them to perform their activities under such arrangements, in accordance with the highest
ethical standards and best industry practices, including without limitation any voluntary codes of practice applicable in the industry
for the research. Each Party agrees to use commercially reasonable efforts to help ensure that the other Party does not fail to
meet such aim with respect to activities hereunder through any violation of the Canadian Corruption of Foreign Public Officials
Act (the “CFPOA”) or the U.S. Foreign Corrupt Practices Act (the “FCPA”), as applicable.

 

		1.2.	Each Party shall comply with all applicable Laws concerning its efforts in any country or jurisdiction
where it is providing work hereunder or otherwise applying to any of its activities under this Agreement. Neither party shall perform
any actions that are prohibited by local and other anti-corruption laws, including the CFPOA or the FCPA (collectively “Anti-Corruption
Laws”) that may be applicable to one or both parties to the Agreement. Without limiting the foregoing, neither party
shall make any payments, or offer or transfer anything of value, to any government official or government employee, to any political
party official or candidate for political office or to any other third party related to the transaction in a manner that would
violate Anti-Corruption Laws.

 

		1.3.	Health Care Professionals Engaged on Behalf of Each Party.  “Health Care Professional”
or "HCP" is defined as (i) any person who is licensed by a province or state to provide health care services directly
or indirectly to patients, such as a physician, a nurse, a technician, a psychologist, or a lab specialist and/or (ii) any person
or organization to whom Zomedica markets its products and services that is in a position to influence the selection of the products
furnished or purchased, including but not limited to hospitals and health systems, administrators, procurement personnel, group
purchasing organizations, pharmacy benefit managers, and business people. In the case of use of animals, Health Care Professional
includes and Veterinarian assistants and technicians.

 

		1.4.	Compliance Obligations Related to Engagement of Health Care Professionals.  If applicable,
the Parties shall, with respect to each HCP engaged under this Agreement or the Development Plan:

 

a. 
ensure that the HCP’s services are provided in compliance with all applicable laws and regulations, including but not limited
to: Laws pertaining to the promotion of products regulated by (i) the Health Canada or the United States Food and Drug Administration
(FDA), (ii) the Canadian Competition Bureau or the U.S. Federal Trade Commission, and (iii) other state, provincial or federal
regulatory agencies; laws, regulations and guidance pertaining to federal, provincial and state anti-kickback and submission of
false claims to governmental or private health care payors, or (iv) applicable analogous or corresponding laws of the applicable
jurisdiction (collectively, “Health Care Compliance” or “HCC”); provincial, state and federal laws and
regulations relating to the protection of individual and patient privacy; and any other laws and regulations applicable to such
services;

 

b.  ensure that HCP’s
services are provided in compliance with each Party’s written policies and procedures of which the other Party is provided
notice, including, but not limited to, applicable policies and procedures related to the U.S. FDA and Health Care Compliance, Health
Canada, the Canadian Food and Drugs Act and Regulations, the Canadian Personal Information Protection and Electronic
Documents Act (“PIPEDA”), substantially similar provincial legislation and the protection of individual and patient
privacy;

 

    
	 	42	 
	 	Confidential	 

     

    

c. ensure that each HCP is:

 

(i)  not excluded from a U.S. Federal health care
program as outlined in Sections 1128 and 1156 of the Social Security Act (see the Office of Inspector General of the Department
of Health and Human Services List of Excluded Individuals/Entities at http://www.oig.hhs.gov/FRAUD/exclusions/listofexcluded.html)
or any Canadian health care or animal care programs;

 

(ii)  not debarred by the U.S. FDA under 21 U.S.C.
335a (see the FDA Office of Regulatory Affairs Debarment List at http://www.fda.gov/ora/compliance_ref/debar/);

 

(iii)  not otherwise excluded from contracting
with the U.S. federal government (see the Excluded Parties Listing System at http://epls.arnet.gov) to the extent that foreign
entities are not restricted from contracting with the U.S. federal government or the Canadian federal or provincial governments;
and

 

(iv) for HCPs (including veterinarians) who are health
care practitioners, duly licensed in the state or province where he or she is currently practicing and not on probation and have
never been on probation with the agency or board or college responsible for his or her licensure;

 

d.  ensure that each HCP
is qualified and authorized to perform the services as may be agreed to by Celsee and Zomedica in the Development Plan, or required
by Law or any applicable authority, including, but not limited to, any required ethics or other authorizations from federal, state,
provincial or local government agencies for HCPs who are employees of such agencies.  Also, Each Party shall ensure that each
HCP is not limited in providing these services by any obligation to third parties; and

 

e.  compensate each HCP the
fair market value for his/her services, based on the services provided, and in a manner that does not take into account the volume
or value of any prescriptions, referrals or business generated among the parties.  

 

		1.5	Promotion of Zomedica’s products. Celsee shall not make any representation relating to Zomedica’s products
or to Zomedica’s clinical (animal) outcomes, unless such representations have been reviewed and approved in advance by Zomedica. 
Celsee further agrees that, in the event that Celsee fails to observe any limitations imposed by the Zomedica on such product representations
or representations concerning clinical outcomes, Zomedica shall have the right to immediately terminate this Agreement.

 

		1.6	Protected Health Information under the Canadian PIPEDA, substantially similar provincial legislation such as the Ontario
Personal Health Information Protection Act, 2004 and the U.S. HIPAA.  If applicable, in the event that the Development
Plan requires the use or disclosure of Personal Health Information or Protected Health Information (as defined under PIPEDA, substantially
similar provincial legislation or the U.S. HIPAA Privacy Requirements or analogous legislation of the applicable jurisdiction)
by HCPs, each Party shall ensure that the program complies with any applicable privacy laws, including as applicable the PIPEDA
(and substantially similar provincial legislation, such as the Ontario Personal Health Information Protection Act, 2004)
and HIPAA Privacy Requirements that apply to such Personal Health Information or Protected Health Information.  The “HIPAA
Privacy Requirements” refer collectively to the applicable provisions of the Administrative Simplification section of HIPAA
- the Health Insurance Portability and Accountability Act of 1996, (as codified at 42 U.S.C. § 1320d - d-8) and any regulations
promulgated there under, including without limitation, the federal privacy regulations (45 CFR Parts 160 and 164) and the federal
security standards (45 CFR Part 142).

 

    
	 	43	 
	 	Confidential	 

     

    

		1.7	Consent to Use and Disclose Information.  If applicable, in the event that the Development Plan requires direct
interactions with patients, consumers or caregivers, each Party shall obtain written consent from any such person providing each
Party the right to use and disclose the information collected from such persons, as set forth in the Development Plan. To the extent
that the Development Plan or activities requires testing or application to animals, then the Parties shall comply with the applicable
Laws and highest ethical standards governing animal testing and welfare, such as in the United States, the Animal Welfare Act of
1966 (“AWA”), and the Animal Welfare Regulations and provide for an Institutional Animal Care and Use Committee (“IACUC”).

 

 

 

 

 

 

 

    
	 	44	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

SCHEDULE D

CUSTOMER SERVICE REQUIREMENTS

 

[*]

 

 

 

 

 

 

    
	 	45	 
	 	Confidential	 

     

    
[*Confidential Treatment has been
requested as to certain portions of this document. Each such portion, which has been omitted herein and replaced with an asterisk
[*], has been filed separately with the Securities and Exchange Commission.]

 

SCHEDULE
E

QUALITY CONTROL

 

[*]

 

 

 

 

 

 

 

    
	 	46	 
	 	Confidential	 

     

    

Schedule F – Private Placement
and Registration Rights Rider

 

 

(a)                  
In connection with the issuance of Zomedica shares to Celsee, Celsee makes the following representations and warranties
to Zomedica set forth in subsection (b) below, and Zomedica makes the following covenants to Celsee, set forth in subsections (c)
– (r) below.

 

 (b)                  
Celsee hereby represents and warrants to Zomedica as follows:

 

(i)                
On the date hereof and on each date on which it receives Zomedica common shares hereunder (collectively, the “Securities”),
Celsee is and will be an “accredited investor” as defined in Rule 501(a) under the Securities Act of 1933, as amended
(the “Securities Act”). Celsee maintains its principal executive office at the location specified in the introductory
paragraph of this Agreement.

 

(ii)              
The Securities to be received by Celsee hereunder will be acquired for such Investor’s own account, not as nominee
or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and Celsee
has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities
Act without prejudice, however, to Celsee’s right at all times to sell or otherwise dispose of all or any part of such Securities
in compliance with applicable federal and state securities laws. Nothing contained herein shall be deemed a representation
or warranty by Celsee to hold the Securities for any period of time. Such Investor is not a broker-dealer registered with the Securities
and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934, as amended (the “Exchanger
Act”), or an entity engaged in a business that would require it to be so registered.

 

(iii)            
Celsee acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has such
knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment
contemplated hereby.

 

(iv)            
Celsee has had an opportunity to receive all information related to Zomedica requested by it and to ask questions of and
receive answers from Zomedica regarding Zomedica, its business and the terms and conditions of the Securities. Celsee acknowledges
that it has had access to Zomedica’s filings with the Commission as well as filings made by Zomedica with applicable Canadian
securities regulators.

 

(v)              
Celsee understands that the Securities are characterized as “restricted securities” under the U.S. federal securities
laws inasmuch as they are being acquired from Zomedica in a transaction not involving a public offering and that under such laws
and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited
circumstances.

 

    
	 	47	 
	 	Confidential	 

     

    

(vi)            
Celsee did not learn of the investment in the Securities as a result of any general solicitation or general advertising.

 

(vii)          
Celsee acknowledges and understands that because Zomedica was previously a “shell company” as defined in Rule
405 under the Securities Act, the provisions of Rule 144(i) under the Securities Act will apply with respect to any resale of the
Securities pursuant to such Rule 144.

 

(viii)        
Celsee acknowledges and understands that certificates evidencing the Securities will bear the following or any similar legend:

 

“The
securities represented hereby have not been registered with the Securities and Exchange Commission or the securities commission
of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may
not be transferred unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended,
(ii) such securities are sold pursuant to Rule 144, or (iii) the Company has received an opinion of counsel reasonably satisfactory
to it that such transfer may lawfully be made without registration under the Securities Act of 1933, as amended.”

 

(c)   
Following the issuance of any Securities to Celsee under the Agreement, Zomedica shall use its commercially reasonable efforts
to register such Securities for resale or other disposition by Celsee within 90 days of the date of such receipt. Zomedica shall
notify Celsee promptly upon effecting such registration. Subject to any permitted “Black-Out Periods” (as described
below), Zomedica shall use its commercially reasonable efforts to maintain the effectiveness of any such registration until the
earlier of (i) the date on which all of the Securities so registered have been sold by Celsee or its transferees or (ii) the date
on which such Securities may be sold under Rule 144 (the period of such registration being referred to herein as the “Registration
Period”). Subject to any comments from the Staff of the Commission, such Registration Statement shall include the plan of
distribution attached hereto as Exhibit A;

 

(d)  
Zomedica shall have the right to suspend its obligation to register the Securities as provided in clause (c) above or to
maintain the registration of such Securities during the Registration Period and the use of any prospectus during the Registration
Period as follows: (i) for a period commencing on December 15 of any calendar year until such time as either (A) a post-effective
amendment to any registration statement on Form S-1 registering the Securities containing audited financial statements for the
year then ended is declared effective by the Commission or (B) Zomedica files its Annual Report on Form 10-K in the case of any
registration statement on Form S-3 registering the Securities, (ii) for such period of time as determined by Zomedica in the good
faith exercise of its business judgment if Zomedica furnishes to Celsee a certificate signed by Zomedica’s chief executive
officer or chief financial officer stating that in his or her good faith judgment it would be materially detrimental to Zomedica
and its shareholders for such registration statement to either become effective or remain effective because such action would (A)
materially delay, hinder or otherwise interfere with a material acquisition, corporate reorganization, collaboration, joint venture
or other similar transaction involving Zomedica; (B) require the disclosure of material non-public information that Zomedica has
a bona fide business purpose for preserving as confidential; (C) render Zomedica unable to comply with requirements under the Securities
Act or Exchange Act, then Zomedica shall have the right to defer taking action with respect to such filing; or (D) interfere in
any material respect with a proposed capital raise by Zomedica; or (iii) for such period of time as determined by Zomedica to amend
or supplement the registration statement or prospectus covering such Securities so that registration statement or prospectus shall
not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein, in the case of the prospectus in light of the circumstances under which they were made, not misleading.
Each of such periods is referred to herein as a “Black-Out Period.” Except for any Black-Out Period arising pursuant
to clause (i) above, no Black-Out Period shall continue for more than 60 days and the total Black-Out Periods in any 12-month period
shall not exceed a total of 120 days. During any Black-Out Period (other than a Black-Out Period covered by clause (ii)(D) above),
Zomedica shall not effect the registration of securities for its own account or the account of another selling shareholder. Zomedica
shall promptly (i) notify Celsee in writing of the commencement of a Black-Out Period, but shall not (without the prior written
consent of Celsee) disclose to Celsee any material non-public information giving rise to a Black-Out Period, (ii) advise Celsee
in writing to cease all sales of the Securities under the related registration statement and prospectus until the end of the Black-Out
Period and (iii) use its commercially reasonable efforts to terminate a Black-Out Period as promptly as practicable.

 

    
	 	48	 
	 	Confidential	 

     

    

(e)   
Except during a Black-Out Period, Zomedica shall promptly notify Celsee, at any time prior to the end of the Registration
Period, upon discovery that, or upon the happening of any event as a result of which, the registration statement or prospectus
covering the Securities includes an untrue statement of a material fact or omits to state a material fact required to be stated
therein or necessary to make the statements therein, in the case of the prospectus in light of the circumstances under which they
were made, not misleading, and promptly (but in any event within thirty (30) days) prepare, file with the Commission and furnish
to Celsee (including delivery pursuant to Rule 172 under the Securities Act) a supplement to or an amendment of such registration
statement or prospectus as may be necessary to correct such misstatement or omission.

 

(f)   
Celsee shall furnish in writing to Zomedica the information set forth in the selling shareholder’s questionnaire attached
hereto as Exhibit B to effect the registration of such Securities and shall execute such documents in connection with such
registration as Zomedica may reasonably request. Celsee shall provide such information to Zomedica at least two (2) business days
prior to the first anticipated filing date of the related registration statement. In the event that Celsee fails to provide a completed
questionnaire on a timely basis and such failure continues for a period of five (5) business days after Zomedica provides Celsee
with written notice of such failure, Zomedica’ s obligation to register such Securities shall terminate with respect to such
Securities.

 

    
	 	49	 
	 	Confidential	 

     

    

(g)  
Celsee agrees to cooperate with Zomedica as reasonably requested by Zomedica in connection with the preparation and filing
of a registration statement hereunder, unless Celsee has notified Zomedica in writing of its election to exclude its Securities
from such registration statement

 

(h)  
Celsee agrees that, upon receipt of any notice from Zomedica (i) during any permitted Black-Out Period or (ii) the happening
of an event pursuant to clause (e) above, Celsee will immediately discontinue disposition of Securities pursuant to the registration
statement covering such Securities, until such permitted Black-Out Period has ended or Celsee is advised by Zomedica that such
dispositions may again be made.

 

(i)    
If at any time following the date of this Agreement that any Securities are not eligible for sale under Rule 144 (i) there
is not one or more effective registration statements covering the Securities and (ii) Zomedica proposes for any reason to register
any Common Shares under the Securities Act (other than pursuant to a registration statement on Form S-4 or Form S-8 (or a similar
or successor form)) with respect to an offering of Common Shares by Zomedica for its own account or for the account of any of its
shareholders, it shall at each such time promptly give written notice to Celsee of its intention to do so (but in no event less
than twenty (20) days before the anticipated filing date) and, to the extent permitted under the provisions of Rule 415 under the
Securities Act (if the registration is a shelf registration) and pari passu with the terms of any registration rights granted
to other shareholders, include in such registration all Securities with respect to which Celsee requests in writing be included
therein within ten (10) days after receipt of Zomedica’s notice. Such notice shall offer Celsee the opportunity to register
such number of Securities as Celsee may request and shall indicate the intended method of distribution of securities covered by
such registration statement.

 

(j)    
Notwithstanding the foregoing, (i) if Celsee has exercised its option to include some or all of its Securities in an offering
under (i) above, and such registration involves an underwritten public offering, (A) Celsee must sell its Securities to, if applicable,
the underwriter(s) at the same price and subject to the same underwriting discounts and commissions that apply to the other securities
sold in such offering and subject to Celsee entering into customary underwriting documentation for selling shareholders in an underwritten
public offering, and (B) Celsee’s right to include Securities in such registration shall be subject to cut-back (pro rata
with any other selling shareholders seeking to include their securities in such registration) in the event that the managing underwriter
of such offering determines that the inclusion of all or some of such Securities would be impracticable or inadvisable, and (ii)
if, at any time after giving written notice of its intention to register any Securities pursuant to clause (i) above and prior
to the effective date of the registration statement filed in connection with such registration, Zomedica shall determine for any
reason not to cause such registration statement to become effective under the Securities Act, Zomedica shall deliver written notice
to Celsee and, thereupon, shall be relieved of its obligation to register any Securities in connection with such registration.

 

    
	 	50	 
	 	Confidential	 

     

    

(k)  
In connection with the registration of Securities hereunder, Zomedica shall:

 

(i)                
Except during any Black-Out Period, prepare and file with the Commission such amendments and supplements to such registration
statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities
Act in order to enable the disposition of all securities covered by such registration statement;

a)                 
 

(ii)              
make available to Celsee an electronic copy of the preliminary and final prospectus in accordance with Rule 173, or in the
alternative, furnish such numbers of hard copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as Celsee may reasonably request in order to facilitate their disposition of their Securities

(iii)            
promptly notify Celsee of the happening of any event as a result of which the prospectus included in such registration statement,
as then in effect, includes an untrue statement of material fact or omits to state a material fact required to be stated therein
or necessary to make the statements therein not misleading in the light of the circumstances then existing;

(iv)            
use its commercially reasonable efforts to cause all such Securities covered by such registration statement to be listed
on each securities exchange and trading system (if any) on which similar securities issued by Zomedica are then listed;

 

(v)              
provide a transfer agent and registrar for all Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Securities, in each case not later than the effective date of such registration;

 

(vi)            
notify Celsee promptly after Zomedica receives notice thereof, of the time when such registration statement has been declared
effective or a supplement to any prospectus forming a part of such registration statement has been filed;

 

    
	 	51	 
	 	Confidential	 

     

    

(vii)          
after such registration statement becomes effective, notify Celsee of any request by the Commission that Zomedica amend
or supplement such registration statement or prospectus; and,

 

(viii)        
in connection with any sale or other disposition of Securities pursuant to Rule 144, cooperate with Celsee to effect the
removal of any restrictive legend in connection with such sale or other disposition and, in connection therewith, cause its counsel
to provide to the transfer agent for the Securities a customary opinion of counsel that such legend may be removed in connection
with such sale or other disposition provided Celsee has provided to Zomedica such documentation, including a customary broker’s
letter, as Zomedica’s counsel may reasonably request in connection with such opinion.

 

(l)    
Zomedica will pay all of its expenses associated with effecting the registration of the Securities or removal of any Rule
144 legend, including filing and printing fees, Zomedica’s counsel and accounting fees and expenses, costs associated with
clearing the Securities for sale under applicable state securities laws and listing and transfer agent fees. Celsee shall be responsible
for its own fees and expenses in connection with any such registration, including its counsel and accounting fees, discounts, commissions,
fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect to the Securities
being sold.

 

(m) To the
extent permitted by law, Zomedica will indemnify and hold harmless Celsee and its officers and directors and each person, if any,
who controls Celsee within the meaning of the Securities Act (collectively, “Celsee Indemnified Parties”), against
any Damages (defined below), and Zomedica will promptly reimburse such Celsee Indemnified Parties for all reasonable out-of-pocket
costs and expenses (including the reasonable fees and disbursements of counsel) in connection with investigating or defending any
claim or proceeding for Damages as such costs and expenses are incurred; provided, however, that the indemnity agreement contained
in this subsection (m) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of Zomedica, which consent shall not be unreasonably withheld, nor shall Zomedica be liable for any Damages
to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written
information furnished by or on behalf of Celsee expressly for use in connection with such registration.

 

(n)  
To the extent permitted by law, Celsee will indemnify and hold harmless Zomedica, and each of its directors, each of its
officers who has signed the registration statement and each person, if any, who controls Zomedica within the meaning of the Securities
Act (collectively, “Zomedica Indemnified Party”) against any Damages, in each case only to the extent that such Damages
arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished
by or on behalf of Celsee expressly for use in connection with such registration; and Celsee will promptly reimburse such Zomedica
Indemnified Parties for all reasonable out-of-pocket costs and expenses (including the reasonable fees and disbursements of counsel)
in connection with investigating or defending any claim or proceeding for Damages as such costs and expenses are incurred; provided,
however, that the indemnity agreement contained in this subsection (n) shall not apply to amounts paid in settlement of any such
claim or proceeding if such settlement is effected without the consent of Celsee, which consent shall not be unreasonably withheld;
and provided, further, that in no event shall the aggregate amounts payable by Celsee by way of indemnity or contribution under
this subsection (m) exceed the gross proceeds received by Celsee from the sale of Securities pursuant to such registration.

 

    
	 	52	 
	 	Confidential	 

     

    

(o)  
As used herein, the term “Damages” shall mean any loss, damage, or liability (joint or several) to which a party
hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage,
or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement
of a material fact contained in any registration statement, prospectus or amendment or supplement thereto; or (ii) an omission
or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein,
except in the case of a registration statement, in light of the circumstances under which they were made not misleading.

 

(p)  
Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any claim with
respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel
reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have
the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel
shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, or (b) the indemnifying
party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in
the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such
person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in
writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall
not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the
failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations
hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the
defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding
in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified
parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter
into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified
party of a release from all liability in respect of such claim or litigation.

 

    
	 	53	 
	 	Confidential	 

     

    

(q)  
To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i)
any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Agreement but it is
judicially determined that such indemnification may not be enforced in such case, or (ii) contribution under the Securities Act
may be required on the part of any party hereto for which indemnification is provided under this Agreement, then, and in each such
case, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Damages
in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well
as any other relevant equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of Section
11(f) of the Securities Act shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation.
In no event shall Celsee’s liability pursuant to this section (q), when combined with the amounts paid or payable by Celsee
pursuant to section (n), exceed the gross proceeds received by Celsee from the sale of Securities pursuant to such registration.

 

(r)    
Celsee’s registration rights as contained herein are personal to Celsee and may not be assigned or otherwise transferred
by Celsee, whether in connection with the sale or other disposition of Securities or otherwise. Any purported assignment or other
transfer shall be null and void ab initio.

 

 

    
	 	54	 
	 	Confidential	 

     

    

Exhibit A

Plan of Distribution

 

The selling shareholders,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling common shares or interests
in common shares received after the date of this prospectus from a selling shareholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their common shares or interests
in common shares on any stock exchange, market or trading facility on which the common shares are traded or in private transactions.
These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing
market price, at varying prices determined at the time of sale, or at negotiated prices.

 

The selling shareholders
may use any one or more of the following methods when disposing of common shares or interests therein:

 

		b)	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

		c)	block trades in which the broker-dealer will attempt to sell the common shares as agent, but may
position and resell a portion of the block as principal to facilitate the transaction;

 

		d)	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

		e)	an exchange distribution in accordance with the rules of the applicable exchange;

 

		f)	privately negotiated transactions;

 

		g)	short sales effected after the date the registration statement of which this Prospectus is a part
is declared effective by the SEC;

 

		h)	through the writing or settlement of options or other hedging transactions, whether through an
options exchange or otherwise;

 

		i)	broker-dealers may agree with the selling shareholders to sell a specified number of common shares
at a stipulated price per share;

 

		j)	a combination of any such methods of sale; and

 

		k)	any other method permitted by applicable law.

 

The selling shareholders
may, from time to time, pledge or grant a security interest in some or all of the common shares owned by them and, if they default
in the performance of their secured obligations, the pledgees or secured parties may offer and sell the common shares, from time
to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of
the Securities Act amending the list of selling shareholders to include the pledgee, transferee or other successors in interest
as selling shareholders under this prospectus. The selling shareholders also may transfer the common shares in other circumstances,
in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.

 

    
	 	55	 
	 	Confidential	 

     

    

In connection with the
sale of our common shares or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common shares in the course of hedging the positions
they assume. The selling shareholders may also sell common shares short and deliver these common shares to close out their short
positions, or loan or pledge the common shares to broker-dealers that in turn may sell these common shares. The selling shareholders
may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or
more derivative securities which require the delivery to such broker-dealer or other financial institution of common shares offered
by this prospectus, which common shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).

 

The aggregate proceeds
to the selling shareholders from the sale of the common shares offered by them will be the purchase price of the common shares
less discounts or commissions, if any. Each of the selling shareholders reserves the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common shares to be made directly or through agents.
We will not receive any of the proceeds from this offering.

 

The selling shareholders
also may resell all or a portion of the common shares in open market transactions in reliance upon Rule 144 under the Securities
Act, provided that they meet the criteria and conform to the requirements of that rule.

 

The selling shareholders
and any underwriters, broker-dealers or agents that participate in the sale of the common shares or interests therein may be "underwriters"
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the common shares may be underwriting discounts and commissions under the Securities Act. Selling shareholders who are "underwriters"
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.

 

To the extent required,
the common shares to be sold, the names of the selling shareholders, the respective purchase prices and public offering prices,
the names of any agent, dealer or underwriter and any applicable commissions or discounts with respect to a particular offer will
be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.

 

In order to comply with
the securities laws of some states, if applicable, the common shares may be sold in these jurisdictions only through registered
or licensed brokers or dealers. In addition, in some states the common shares may not be sold unless it has been registered or
qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

 

    
	 	56	 
	 	Confidential	 

     

    

We have advised the selling
shareholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of common shares in the
market and to the activities of the selling shareholders and their affiliates. In addition, to the extent applicable we will make
copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling shareholders for the
purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling shareholders may indemnify any broker-dealer
that participates in transactions involving the sale of the common shares against certain liabilities, including liabilities arising
under the Securities Act.

 

We have agreed to indemnify
the selling shareholders against liabilities under the Securities Act relating to the registration of the common shares offered
by this prospectus.

 

We have agreed with the
selling shareholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier
of (i) the date on which all of the common shares have been sold by the selling shareholders or (ii) the date on which the common
shares may be sold under Rule 144.

 

 

    
	 	57	 
	 	Confidential	 

     

    

Exhibit B to Schedule
F

 

Zomedica Pharmaceuticals
Corp.

 

Selling Shareholder Notice and Questionnaire

 

The undersigned beneficial owner of common
shares, without par value (“Common Shares”), of Zomedica Pharmaceuticals Corp. (the “Company”)
understands that, pursuant to the License Agreement, dated [DATE], it will be named as a selling shareholder in the prospectus
that forms a part of the Company's Registration Statement on Form S-1 (the “Registration
Statement”). The Registration Statement registers for resale under the Securities Act of 1933, as amended (the
“Securities Act”), the Common Shares the undersigned beneficially owns
that are disclosed in response to Question 5(b) of this Questionnaire (the “Registrable
Securities”). The Company will use the information that the undersigned provides in this Questionnaire to ensure
the accuracy of the Registration Statement and the prospectus.

 

Certain legal consequences arise from being
named as a selling shareholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners
of securities to be registered under the Registration Statement are advised to consult their own securities counsel regarding the
consequences of being named or not being named as a selling shareholder in the Registration Statement and the related prospectus.

 

The undersigned acknowledges that by completing,
dating, executing and returning this Questionnaire to the Company, it is giving written notice to the Company of its desire to
have the Common Shares disclosed in response to Question 5(b) of this Questionnaire included in the Registration Statement.

 

Please answer every question.

 

If the answer to any question is “none”
or “not applicable,” please so state.

 

1.                 
Name. Type or print the full legal name of the selling shareholder.

	 	 

 

2.                 
Contact Information. Provide the address, telephone number, fax number and email address of the selling shareholder.

 

	Address:	 	 
	 	 	 
	Phone:	 	 
	Fax:	 	 
	Email:	 	 

    
	 	58	 
	 	Confidential	 

     

    

3.                 
Relationship with the Company. Describe the nature of any position, office or other material relationship the selling
shareholder has had with the Company during the past three years.

	 	 
	 	 

 

4.                 
Organizational Structure. Please indicate or (if applicable) describe how the selling shareholder is organized.

 

	
        Is the selling shareholder a natural person?

         

        (If so, please mark the box and skip to Question 5.)

         
	___ Yes	 ___ No	 

 

	
        Is the selling shareholder a reporting company under the Securities
        Exchange Act of 1934, as amended (the “Exchange Act”)?

         

        (If so, please mark the box and skip to Question 5.)

         
	___ Yes	 ___ No	 

 

	
        Is the selling shareholder a majority-owned subsidiary of a
        reporting company under the Exchange Act?

         

        (If so, please mark the box and skip to Question 5.)

         
	___ Yes	 ___ No	 

 

	
        Is the selling shareholder a registered investment company under
        the Investment Company Act of 1940?

         

        (If so, please mark the box and skip to Question 5.)

         
	___ Yes	 ___ No	 

    
	 	59	 
	 	Confidential	 

     

    

If the answer to all of the foregoing questions
is “no,” please describe: (i) the exact legal description of the selling shareholder (e.g., corporation, partnership,
limited liability company, etc.); (ii) whether the legal entity so described is managed by another entity and the exact legal description
of such entity (repeat this step until the last entity described is managed by a person or persons, each of whom is described in
any one of (a) through (d) above); (iii) the names of each person or persons having voting and investment control over the Company's
securities that the entity owns (e.g., director(s), general partner(s), managing member(s), etc.).

 

(a)               
Legal Description of Entity:

	 	 

 

(b)              
Name of Entit(ies)/(y) Managing Such Entity (if any):

	 	 
	 	 

 

(c)               
Name of Entit(ies)/(y) Managing such Entit(ies)/(y) (if any):

	 	 
	 	 

 

(d)              
Name(s) of Natural Person(s) Having Voting or Investment Control Over the Shares Held by such Entit(ies)/(y):

	 	 

 

5.                 
Ownership of the Company’s Securities. This question covers beneficial ownership of the Company’s securities.
Please consult Appendix A to this Questionnaire for information as to the meaning of “beneficial ownership.”
State (a) the number of Common Shares (including any Common Shares issuable upon exercise of warrants or other convertible securities)
that the selling shareholder beneficially owned as of the date this Questionnaire is signed and (b) the number of such Common Shares
that the selling shareholder wishes to have registered for resale in the Registration Statement:

 

(a)               
Number of Common Shares and other equity securities owned:

	 	 

 

(b)              
Number of Common Shares owned to be registered for resale in the Registration Statement:

	 	 

 

6.                 
Acquisition of Common Shares. If the selling shareholder did not acquire the Common Shares to be sold directly from
the Company please describe below the manner in which the Common Shares were acquired including, but not limited to, the date,
the name and address of the seller(s), the purchase price and pursuant to which documents (the “Acquisition Documents”)
and please forward such documents as provided below.

	 	 
	 	 

 

    
	 	60	 
	 	Confidential	 

     

    

7.                 
Broker-Dealer Status.

 

(a)               

	Is the selling shareholder a broker-dealer?	___ Yes	 ___ No	 
	 	 	 	 

(b)              

	
        If the answer to Section 7(a) is “yes,” did the
        selling shareholder receive the Registrable Securities as compensation for investment banking services to the Company?

         

        Note: If the answer to 7(b) is “no,” SEC guidance
        has indicated that the selling shareholder should be identified as an underwriter in the Registration Statement.

        
	___ Yes	 ___ No	 
	 	 	 	 

(c)               

	Is the selling shareholder an affiliate of a broker-dealer?	___ Yes	 ___ No	 
	 	 	 	 

(d)              

	
        If the selling shareholder is an affiliate of a broker-dealer,
        does the selling shareholder certify that it purchased the Registrable Securities in the ordinary course of business, and at the
        time of the purchase of the Registrable Securities to be resold, the selling shareholder had no agreements or understandings, directly
        or indirectly, with any person to distribute the Registrable Securities?

         

        Note: If the answer to 7(d) is “no,” SEC guidance
        has indicated that the selling shareholder should be identified as an underwriter in the Registration Statement.

         
	___ Yes	 ___ No	 

    
	 	61	 
	 	Confidential	 

     

    

8.                 
Plan of Distribution. The undersigned has reviewed the proposed “Plan of Distribution” section in the
Registration Statement and agrees that the statements contained therein reflect its intended method(s) of distribution. The undersigned
agrees that it will only sell the Registrable Securities pursuant to the Registration Statement in accordance with such “Plan
of Distribution.”

 

9.                 
Legal Proceedings with the Company. Is the Company a party to any pending legal proceeding in which the selling shareholder
is named as an adverse party?

 

	 	___ Yes	 ___ No	 

State any exceptions here:

	 	 
	 	 

 

10.             
Reliance on Responses. The undersigned acknowledges and agrees that the Company and its legal counsel shall be entitled
to rely on its responses in this Questionnaire in all matters pertaining to the Registration Statement and the sale of any Registrable
Securities pursuant to the Registration Statement.

 

The undersigned hereby acknowledges and
is advised of the SEC’s Compliance and Disclosure Interpretation 239.10 regarding short selling:

 

“An Issuer filed a Form S-3 registration
statement for a secondary offering of common stock which is not yet effective. One of the selling shareholders wanted to do a short
sale of common stock “against the box” and cover the short sale with registered shares after the effective date. The
issuer was advised that the short sale could not be made before the registration statement become effective, because the shares
underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of Section
5 if the shares were effectively sold prior to the effective date.”

 

By returning this Questionnaire, the undersigned
will be deemed to be aware of the foregoing interpretation.

 

If the Company is required to file a new
or additional registration statement to register Registrable Securities beneficially owned by the selling shareholder, the undersigned
hereby agrees to complete and return to the Company, upon the request of the Company, a new Questionnaire (in a form substantially
similar to this Questionnaire).

 

If the selling shareholder transfers all
or any portion of its Registrable Securities after the date on which the information in this Questionnaire is provided to the Company,
the undersigned hereby agrees to notify the transferee(s) at the time of transfer of its rights and obligations hereunder.

    
	 	62	 
	 	Confidential	 

     

    

By signing below, the undersigned represents
that the information provided herein is accurate and complete. The undersigned agrees to promptly notify the Company of any inaccuracies
or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement
remains effective.

 

By signing below, the undersigned consents
to the disclosure of the information contained herein and the inclusion of such information in the Registration Statement and the
related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied
upon by the Company and its counsel in connection with the preparation or amendment of the Registration Statement and the related
prospectus.

 

 

 

[Signature Page Immediately Follows]

 

    
	 	63	 
	 	Confidential	 

     

    

IN WITNESS WHEREOF the undersigned, by authority
duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.

 

	Dated: ___________________	
        Beneficial Owner:

        ___________________________

        By:___________________________

        [Name:]

        [Title:]

	 	 

 

AS SOON AS POSSIBLE, PLEASE FAX A COPY OF THE
COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:

 

	 	John D. Hogoboom
	 	Lowenstein Sandler LLP
	 	One Lowenstein Drive
	 	Roseland, NJ 07068
	 	Fax:  (973) 597-2383
	 	Email:  jhogoboom@lowenstein.com

 

 

 

 

    
	 	64	 
	 	Confidential	 

     

    

APPENDIX
A

 

Definition
of “Beneficial Ownership”

 

1.       A
“Beneficial Owner” of a security includes any person who, directly or indirectly, through any contract, arrangement,
understanding, relationship or otherwise has or shares:

 

(a) Voting power which includes the power
to vote, or to direct the voting of, such security; and/or

 

(b) Investment power which includes the power
to dispose, or direct the disposition of, such security.

 

Please note that either voting power or investment
power, or both, is sufficient for you to be considered the beneficial owner of shares.

 

2.       Any
person who, directly or indirectly, creates or uses a trust, proxy, power of attorney, pooling arrangement or any other contract,
arrangement or device with the purpose or effect of divesting such person of beneficial ownership of a security or preventing the
vesting of such beneficial ownership as part of a plan or scheme to evade the reporting requirements of the federal securities
acts shall be deemed to be the beneficial owner of such security.

 

3.       Notwithstanding
the provisions of paragraph (1), a person is deemed to be the “beneficial owner” of a security if that person has the
right to acquire beneficial ownership of such security within 60 days, including but not limited to any right to acquire: (a) through
the exercise of any option, warrant or right; (b) through the conversion of a security; (c) pursuant to the power to revoke a trust,
discretionary account or similar arrangement; or (d) pursuant to the automatic termination of a trust, discretionary account or
similar arrangement; provided, however, any person who acquires a security or power specified in (a), (b) or (c) above, with the
purpose or effect of changing or influencing the control of the issuer, or in connection with or as a participant in any transaction
having such purpose or effect, immediately upon such acquisition shall be deemed to be the beneficial owner of the securities which
may be acquired through the exercise or conversion of such security or power.

 

 

 

 

65

ConfidentialExhibit 10.1

  

EXCHANGE AGREEMENT

 

This EXCHANGE AGREEMENT
(the “Agreement”) is entered into February 26, 2018, by and among One Horizon Group, Inc., a Delaware corporation
(“OHGI”), C-Rod, Inc., a Florida corporation (the “Company”), which includes any and all
business conducted under the trade names Mues Media and/or Velveteen Entertainment, Christopher Robin Rodriguez (hereinafter, “Rodriguez”)
and Patricia Nieto Rodriguez (hereinafter, “Nieto”), the stockholders of the Company (together, the “Stockholders”),
upon the following premises:

 

Preliminary Statement

 

OHGI is a publicly
traded corporation whose shares of common stock, par value $0.0001 per share (“OHGI Common Stock”), are listed
on the NASDAQ Capital Market (“NASDAQ”) and registered under Section 12(b) of the Securities Exchange Act of
1934, as amended (“Exchange Act”).

 

The Stockholders own
all of the outstanding shares of the capital stock of the Company (the “Company Shares”). OHGI desires to acquire
the Company Shares from the Stockholders in exchange for $150,000 (the “Cash Exchange Consideration”) and 1,000,000
shares of OHGI Common Stock (the “Initial Shares”), plus an additional number of shares of OHGI Common Stock
computed in accordance with the provisions of Section 5.02 of this Agreement (“Additional Shares,” and
together with the Initial Shares, the “Exchange Shares”), and the Stockholders are willing to exchange their
Company Shares for the Cash Exchange Consideration and the Exchange Shares, on the terms and subject to the conditions set forth
herein (“Exchange”).

 

The board of directors
of OHGI (“Board of OHGI”) and the Company (the “Company Board”) have determined that the
transaction contemplated hereby is desirable and in the best interests of OHGI’s shareholders and the Stockholders. This
Agreement is being entered into for the purpose of setting forth the terms and conditions of the proposed Exchange.

 

NOW THEREFORE,
on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth and the mutual
benefits to the parties to be derived here from, and intending to be legally bound hereby, it is hereby agreed as follows:

 

ARTICLE I 

REPRESENTATIONS, COVENANTS, AND WARRANTIES
OF THE COMPANY

 

As an inducement to
the consummation of the Exchange, the Company and the Stockholders (collectively, the “Company Parties”), jointly
and severally, represent and warrant that, except as set forth in the schedules of exceptions to the representations of the Company
Parties annexed hereto (“Company Disclosure Schedules”), as of the date hereof and the Closing Date (as defined
in Section 4.02 hereof):

 

1.01 Organization
and Qualification.

 

(a) The Company is
duly incorporated, validly existing, and in good standing under the laws of the State of Florida and has the corporate power and
is duly authorized under all applicable laws, regulations, ordinances and orders of public authorities, to carry on its business
in all material respects as it is now being conducted. The Company has not qualified to do business in any State other than Florida.
To the knowledge of the Company, no proceeding has been instituted in any jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail the power and authority or qualification of the Company within such jurisdiction.

 

(b) The Company has
made available to OHGI complete and correct copies of its corporate documents as found at Sunbiz.org (collectively, the “Company
Charter Documents”). The execution and delivery of this Agreement does not, and the consummation of the transactions
contemplated hereby will not, violate any provision of the Company Charter Documents. The Company has taken all actions required
by law and the Company Charter Documents, or otherwise, to authorize the execution and delivery of this Agreement.

 

    1 

     

    

 

1.02 Power and Authority.
The Company has all requisite power and authority to execute, deliver and perform its obligations under this Agreement and to consummate
the transactions contemplated hereby.

 

1.03 Authorization
of Agreement; Due Execution and Delivery; Binding Agreement. The execution, delivery and performance of this Agreement by the
Company, and the consummation of the transactions contemplated hereby, have been duly authorized by the Company Board and no further
corporate action is required, and the Company Board has recommended that the Stockholders accept the Exchange. This Agreement has
been duly executed and delivered on behalf of the Company. This Agreement constitutes a valid and binding obligation of the Company
and the Stockholders, enforceable in accordance with its terms, except that such enforcement may be limited by bankruptcy, insolvency
or other similar laws affecting the enforcement of creditors, rights generally, and subject to the qualification that the availability
of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

 

1.04 No Conflict.
 The execution of this Agreement and the consummation of the transactions contemplated by this Agreement (i) will not violate
any provision of the Company Charter Document; (ii) will not, with or without notice, lapse of time or both, result in the breach
of any term or provision of, constitute a default under, or terminate, accelerate or modify the terms of any indenture, mortgage,
deed of trust, or other material agreement, or instrument to which the Company is a party or to which any of its assets, properties
or operations are subject; (iii) violate any provision of law, statute, rule, regulation or executive order to which the Company
is subject; or (iv) violate any judgment, order, writ or decree of any court applicable to the Company.

 

1.05 Company Capital
Stock. As of the date hereof, all of the authorized capital stock of the Company issued and outstanding is owned by the Stockholders
party hereto. All of the Company Shares have been duly authorized, are fully paid and non-assessable. None of the Company Shares
were issued in violation of the preemptive or other rights of any Stockholders or other person or entity.

 

1.06 Derivative
Securities.  There are no existing options, warrants, calls, or commitments of any character giving any person or entity
the right to acquire shares of the Company’s capital stock.

 

1.07 Financial Statements.

 

(a) The Company has
made available to OHGI a correct copy of the financial statements of the Company as of December 31, 2017 (the “Financial
Statements”) as well as access to financial information for the fiscal years ended December 31, 2017 and December 31,
2016 (collectively, the “Company Financial Statements”).

 

(b) The Company Financial
Statements are true and accurate and present fairly as of their respective dates the financial results of the Company. As of December
31, 2017, the Company had sufficient working capital to enable the Company to pay all liabilities as they fall due. The Company
has no material liabilities, direct or indirect, matured or not yet matured, contingent or otherwise.

 

(c) The Company has
or is duly and punctually paying all governmental fees and taxes that it has heretofore become liable to pay, which amounts up
to and including the tax year ending December 31, 2016, do not currently exceed more than $6,000 in actual or potential liability.
The Company has made any and all proper declarations and returns for taxation purposes and all information contained in such declarations
and returns is true and complete and full provision or reserves have been made in its financial statements for all governmental
fees and taxation.

 

(d) The books and
records, financial and otherwise, of the Company are in all material aspects complete and correct and have been maintained consistently
throughout the periods involved.

 

Section 1.08 Absence
of Certain Changes or Events. Since December 31, 2017 (the “Cut-Off Date”):

 

(a) There has not
been (i) any material adverse change in the business, operations, properties, assets or condition of the Company, or (ii) any damage,
destruction or loss suffered by the Company (whether or not covered by insurance), materially and adversely affecting the business,
operations, properties, assets or condition of the Company.

 

    2 

     

    

 

(b) The Company has
not (i) amended the Company Charter Documents; (ii) declared or made, or agreed to declare or make any payment of dividends or
distributions of any assets of any kind whatsoever to stockholders or purchased or redeemed, or agreed to purchase or redeem, any
of its capital stock except in contemplation of this Agreement; (iii) waived any rights of value which in the aggregate are outside
of the ordinary course of its business or material considering its business; (iv) made any material change in its method of management,
operation, or accounting; (v) entered into any transactions or agreements other than in the ordinary course of business; (vi) made
any accrual or arrangement for or payment of bonuses or special compensation of any kind or any severance or termination pay to
any present or former officer or employee; (vii) increased the rate of compensation payable or to become payable by it to any of
its officers or directors or any of its salaried employees whose monthly compensation exceed $1,000; or (viii) made any increase
in any profit sharing, bonus, deferred compensation, insurance, pension, retirement, or other employee benefit plan, payment, or
arrangement, made to, for or with its officers, directors, or employees.

 

(c) The Company has
not (i) granted any options, warrants or rights to purchase, or issued any of its securities; (ii) borrowed or agreed to borrow
any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent), except liabilities
incurred in the ordinary course of business; (iii) paid or agreed to pay any material obligations or liabilities (absolute or contingent)
other than current liabilities reflected in or shown on the Company Balance Sheets and current liabilities incurred since the Cut-Off
Date in the ordinary course of business and professional and other fees and expenses in connection with the preparation of this
Agreement and the consummation of the transaction contemplated hereby; (iv) sold or transferred, or agreed to sell or transfer,
any of its assets, properties, or rights (except assets, properties, or rights not used or useful in its business which, in the
aggregate have a value of less than $1,000), or canceled, or agreed to cancel, any debts or claims (except debts or claims which
in the aggregate are of a value less than $1,000); (v) made or permitted any amendment or termination of any contract, agreement,
or license to which it is a party if such amendment or termination is material, considering its business; or (vi) issued, delivered
or agreed to issue or deliver, any stock, bonds or other corporate securities including debentures (whether authorized and unissued
or held as treasury stock), except in connection or contemplation of this Agreement.

 

(d) The Company has
not become subject to any law or regulation which materially and adversely affects, or in the future, may adversely affect, its
business, operations, properties, assets or condition.

 

1.09 Liabilities.
The Company represents and warrants that there are no lines of credit and other indebtedness that has been incurred by the
Company of any kind.

 

1.10 Litigation
and Proceedings.  There are no actions, suits, proceedings, or investigations pending or, to the knowledge of the Company
after reasonable investigation, threatened by or against the Company or affecting the Company or its properties, at law or in equity,
before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind.  The
Company does not have any knowledge of any material default on its part with respect to any judgment, order, injunction, decree,
award, rule, or regulation of any court, arbitrator, or governmental agency or instrumentality or of any circumstances which, after
reasonable investigation, would result in the discovery of such a default.

 

1.11 Compliance.
The Company to its knowledge is not: (i) in default under or in violation of (and no event has occurred that has not been waived
that, with notice, lapse of time or both, would result in a default by the Company under), nor has the Company received notice
of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement
or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation
has been waived); (ii) in violation of any judgment, decree or order of any court, arbitrator or other governmental authority;
or (iii) or has not been, in violation of any statute, rule, ordinance or regulation of any governmental authority, including without
limitation all foreign, federal, state and local laws relating to taxes, registration as a charitable organization, and employment
and labor matters, except in each case as could not have or reasonably be expected to result in a material adverse effect: (A)
on the legality, validity or enforceability of this Agreement; (B) on the results of operations, assets, business, prospects or
condition (financial or otherwise) of the Company; or (C) on the ability of the Company or the Stockholders to perform in any material
respect on a timely basis, his, her or its obligations under this Agreement.

 

    3 

     

    

 

1.12 Regulatory
Permits. The Company possess all certificates, authorizations and permits issued by the appropriate federal, state, local or
foreign regulatory authorities necessary to conduct its businesses as presently conducted as far as the Company is aware and the
Company does not expect that the failure to possess any such permit might reasonably be expected to result in a Material Adverse
Effect (“Material Permits”), and the Company has not received any notice of proceedings relating to the revocation
or modification of any Material Permit.

 

1.13 Contracts.

 

(a)  Schedule
1.13(a) of the Company Disclosure Schedules contains a list of all contracts, agreements, franchises, license agreements,
debt instruments or other commitments to which the Company is a party or by which it or any of its assets, products, technology,
or properties are bound other than those incurred in the ordinary course of business (“Disclosure Documents”).
In the case of oral agreements, Schedule 1.13(a) includes a description thereof. The Schedule 1.13(a) Disclosure
Documents will be provided to OHGI by the Company not less than five (5) business days prior to the Closing Date as currently
scheduled. Specifically, with respect to Rodriguez’ publishing agreement through Rosemine Publishing with Sony/ATV Discos
Music Publishing LLC, Rodriguez has disclosed and OHGI acknowledges that such publishing agreement is personal to Rodriguez and
any rights of Rodriguez thereunder shall continue to belong to Rodriguez and not the Company or OHGI notwithstanding any other
provision of this Agreement. 

 

(b)  All contracts,
agreements, franchises, license agreements, and other commitments to which the Company is a party or by which its properties are
bound and which are material to the operations of the Company taken as a whole are valid and enforceable by the Company in all
respects, except as limited by bankruptcy and insolvency laws and by other laws affecting the rights of creditors generally or
by the terms and conditions set forth in such contracts or agreements;

 

(c) The Company owns,
licenses or has rights to use any and all intellectual property and technology used in the Company’s business, and to its
knowledge the Company’s use of such intellectual property or technology does not infringe upon the intellectual property
rights of any third party; and

 

(d)  Except as
included or described in Schedule 1.13(a) of the Company Disclosure Schedules, the Company is not a party to any oral or
written (i) contract for the employment of any officer or employee; (ii) profit sharing, bonus, deferred compensation, stock option,
severance pay, pension benefit or retirement plan; (iii) agreement, contract, or indenture relating to the borrowing of money;
(iv) guaranty of any obligation; (vi) collective bargaining agreement; or (vii) agreement with any present or former officer or
manager of the Company, which, in each case cannot be terminated by the Company on notice of no more than thirty (30) days at a
cost of no more than $25,000.

 

1.14 Bank Accounts;
Power of Attorney.   Schedule 1.15 of the Company Disclosure Schedules will be provided to OHGI by the Company
not less than five (5) business days prior to the Closing Date as currently scheduled and will set forth a true and complete list
of all accounts with banks, money market mutual funds or securities or other financial institutions maintained by the Company within
the past twelve (12) months, the account numbers thereof, and all persons authorized to sign or act on behalf of the Company.

 

1.15 No Brokers.
The Company has not retained any broker or finder in connection with any of the transactions contemplated by this Agreement, and
has not incurred or agreed to pay, or taken any other action that would entitle any person to receive, any brokerage fee, finder’s
fee or other similar fee or commission with respect to any of the transactions contemplated by this Agreement except as the Company
has otherwise disclosed.

 

1.16 Disclosure.
 All disclosure provided to OHGI regarding the Company, its business and the transactions contemplated hereby, including the
Company Disclosure Schedules to this Agreement, furnished by or on behalf of the Company with respect to the representations and
warranties made herein are true and correct with respect to such representations and warranties and do not contain any untrue statement
of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading. In the event that the Company Disclosure Schedules are not delivered contemporaneously
with the execution of this Agreement, they shall be delivered prior to the Closing Date.

  

    4 

     

    

 

The Company Parties
acknowledge and agree that OHGI has not made, nor is OHGI making, any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth herein.  

 

ARTICLE II

 

REPRESENTATIONS AND WARRANTIES OF THE
STOCKHOLDERS

 

The Stockholders hereby
represent and warrant, severally and solely, to OHGI as follows.

 

2.01 Good Title.
 The Stockholder are the record and beneficial owners of the Company and have good title to the Company Shares and have the
right and authority to sell and deliver such Company Shares, free and clear of all liens, claims, charges, encumbrances, pledges,
mortgages, security interests, options, rights to acquire, proxies, voting trusts or similar agreements, restrictions on transfer
or adverse claims of any nature whatsoever. Upon delivery of any certificate or certificates duly assigned, representing the same
as herein contemplated and/or upon registering OHGI or its designee as the new owner of such Company Shares in the records maintained
by the Company listing the names of its stockholders and their respective ownership of Company Shares, OHGI or its designee will
receive good title to such Company Shares, free and clear of all liens.

 

2.02 Power and Authority.
The Stockholders have the legal power, capacity and authority to execute and deliver this Agreement, to consummate the transactions
contemplated by this Agreement, and to perform such Stockholders’ obligations under this Agreement.  This Agreement
constitutes a legal, valid and binding obligation of the Stockholders, enforceable against the Stockholders in accordance with
the terms hereof.

 

2.03 No Conflicts.
 The execution and delivery of this Agreement by the Stockholders and the performance by the Stockholders of their obligations
hereunder in accordance with the terms hereof (i) will not require the consent of any third party or governmental entity under
any applicable laws; (ii) will not violate any laws applicable to the Stockholders and (iii) will not violate or breach any contractual
obligation to which the Stockholders are a party.

 

2.04 Stockholders
are Acquiring Exchange Shares for Investment and are Accredited Investors.

 

(a) The Stockholders
are acquiring the Exchange Shares for investment for such Stockholders’ own account and not as a nominee or agent, and not
with a view to the resale or distribution.

 

(b) The Stockholders
represent and warrant that such Stockholders (i) can bear the economic risk of such Stockholders’ investments, and (ii) possess
such knowledge and experience in financial and business matters that such Stockholders are capable of evaluating the merits and
risks of the investment in OHGI and OHGI Common Stock.

 

(c) The Stockholders
represent that he and are “Accredited Person(s)” as that term is defined in Rule 501 of Regulation D (“Regulation
D”) promulgated by the Securities and Exchange Commission (“SEC”) under Section 4(a)(2) of the Securities
Act of 1933, as amended (“Securities Act”), and understand and acknowledge that OHGI is relying upon such representation
to qualify for the exemption from the registration requirements of the Securities Act pursuant to Rule 506 of Regulation D, and
that each certificate representing the Exchange Shares shall be endorsed with the following legends, in addition to any other legend
required to be placed thereon by applicable federal or state securities laws:

 

“THE SHARES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS.”

 

    5 

     

    

 

(d) The Stockholders
acknowledge that neither the SEC nor the securities regulatory body of any other jurisdiction, has received, considered or passed
upon the accuracy or adequacy of the information and representations made in this Agreement. 

 

(e) The Stockholders
acknowledge that they carefully reviewed such information as such Stockholders have deemed necessary to evaluate an investment
in OHGI and the OHGI Common Stock. The Stockholders acknowledge that such Stockholders have been furnished all materials that he
and she have requested relating to OHGI and the issuance of the Exchange Shares hereunder, and that such Stockholders have been
afforded the opportunity to ask questions of OHGI’s representatives to obtain any information necessary to verify the accuracy
of any representations or information made or given to the Stockholders. Notwithstanding the foregoing, nothing herein shall derogate
from or otherwise modify the representations and warranties of OHGI set forth in this Agreement, on which each of the Stockholders
have relied in making an exchange of his, her or its Company Shares for the Exchange Shares.

 

(f) Stockholders understand
that the Exchange Shares may not be sold, transferred, or otherwise disposed of without registration under the Securities Act or
an exemption therefrom, and that in the absence of an effective registration statement covering the Exchange Shares or any available
exemption from registration under the Securities Act, the Exchange Shares may have to be held indefinitely. The Stockholders further
acknowledges that the Exchange Shares may not be sold pursuant to Rule 144 promulgated under the Securities Act unless all of the
conditions of Rule 144 are satisfied (including, without limitation, OHGI’s compliance with the reporting requirements under
the Exchange Act).

 

(g) Stockholders agree
that, notwithstanding anything contained herein to the contrary, the warranties, representations, agreements and covenants of such
Stockholders under this Section 3.04 shall survive the Closing for the period set forth in Section 11.01 hereof.

 

ARTICLE III 

REPRESENTATIONS, COVENANTS, AND WARRANTIES
OF OHGI 

 

As an inducement to,
and to obtain the reliance of the Company and its Stockholders, except as set forth in the schedules of exceptions to the representations
of OHGI annexed hereto (“OHGI Disclosure Schedules”), OHGI represents and warrants, as of the date hereof and
as of the Closing Date, as follows:

 

3.01 Organization.
OHGI is a corporation duly incorporated, validly existing, and in good standing under the laws of Delaware and has the corporate
power and is duly authorized under all applicable laws, regulations, ordinances, and orders of public authorities to carry on its
business in all material respects as it is now being conducted.  OHGI has made available to the Company or there has been
available on EDGAR complete and correct copies of the certificate of incorporation and bylaws of OHGI as in effect on the date
hereof. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will
not, violate any provision of OHGI’s certificate of incorporation or by-laws. OHGI has taken all action required by law,
its certificate of incorporation and by-laws, or otherwise to authorize the execution and delivery of this Agreement, and OHGI
has full power, authority, and legal right and has taken all action required by law, its certificate of incorporation and by-laws,
or otherwise to consummate the transactions herein contemplated, except that the issuance of the OHGI Common Stock will require
the consent of NASDAQ; and, if the number of such shares exceeds Nineteen and Nine-Tenths percent (19.9%) of the outstanding shares
of OHGI outstanding on the Closing Date or the date of issuance, the consent of the shareholders of OHGI.

 

3.02 Capitalization.

 

 (a) OHGI’s
authorized capitalization consists of 200,000,000 shares of OHGI Common Stock, of which not more than 35,000,000 shares are issued
and outstanding, and 50,000,000 shares of preferred stock, par value $0.0001 per share, of which no shares are issued and outstanding.
All issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued in violation of the preemptive
or other rights of any person. All outstanding shares OHGI Common Stock have been issued and granted in compliance with all applicable
securities laws and (in all material respects) other applicable laws and regulations.

 

    6 

     

    

 

(b) Except as contemplated
by this Agreement, and as have or will be disclosed in the “SEC Reports” (as defined in Section 3.04)
and except as set forth in Schedule 3.02 (c) of the OHGI Disclosure Schedules, there is no voting trust, proxy, rights plan,
anti-takeover plan or other agreement or understanding to which OHGI is a party or by which it is bound with respect to any equity
security of any class of OHGI, and there are no agreements to which OHGI is a party, or which OHGI has knowledge of, that conflict
with this Agreement or the transactions contemplated herein or otherwise prohibit the consummation of the transactions contemplated
hereunder.

 

(c) Except as contemplated
by this Agreement, and as have or will be disclosed in the SEC Reports and except as set forth in Schedule 3.02 (c) of the OHGI
Disclosure Schedules, there are no registration rights agreements to which OHGI is a party, or which OHGI has knowledge of,
which conflict with this Agreement or the transactions contemplated herein or otherwise prohibit the consummation of the transactions
contemplated hereunder.

 

3.03 Subsidiaries
and Predecessor Corporations. Except as disclosed in the SEC Reports, OHGI does not have any predecessor corporation, no subsidiaries,
and does not own, beneficially or of record, any shares of any other corporation.

 

3.04 SEC Filings;
Financial Statements.

 

(a) OHGI has made available
to the Company and the Members, or there has been available on EDGAR, correct and complete copies of each report, registration
statement and definitive proxy statement filed by OHGI with the SEC since January 1, 2015 (“SEC Reports”). As
of their respective dates, the SEC Reports: (i) were prepared in accordance and complied in all material respects with the requirements
of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the SEC thereunder applicable to
such SEC Reports; and (ii) did not at the time they were filed (and if amended or superseded by a filing prior to the date of this
Agreement then on the date of such filing and as so amended or superseded) contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

(b) Included in the
SEC Reports are the audited consolidated balance sheets of OHGI as of December 31, 2016, and 2015, and the related audited consolidated
statements of operations, stockholders’ equity and cash flows for December 31, 2016, and 2015, together with the notes to
such statements and the opinion of its independent certified public accountants, with respect thereto; and the unaudited consolidated
balance sheets of OHGI as of September 30, 2017, and 2016, and the related unaudited consolidated statements of operations and
cash flows for the three (3) months and nine (9) months ended September 30, 2017, and 2016, together with the notes to such statements.

 

(c) Each set
of financial statements (including, in each case, any related notes thereto) contained in the SEC Reports comply as to form in
all material respects with the published rules and regulations of the SEC with respect thereto, were prepared in accordance with
U.S generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved
(except as may be indicated in the notes thereto) and each fairly presents in all material respects the financial position of OHGI
at the respective dates thereof and the results of its operations and cash flows for the periods indicated, except that the unaudited
interim financial statements were or are subject to normal adjustments, which were not or are not expected to have a Material Adverse
Effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations
of OHGI, taken as a whole.

 

(d) The OHGI balance
sheets are true and accurate and present fairly as of their respective dates the financial condition of OHGI. As of the date of
such balance sheets, except as and to the extent reflected or reserved against therein, OHGI had no liabilities or obligations
(absolute or contingent) that should be reflected in the balance sheets or the notes thereto prepared in accordance with GAAP,
and all assets reflected therein are properly reported and present fairly the value of the assets of OHGI, in accordance with GAAP.
The statements of operations, stockholders’ equity and cash flows reflect fairly the information required by GAAP to be set
forth therein. All of OHGI’s assets are reflected on its financial statements, and, except as set forth in the OHGI Disclosure
Schedules or the financial statements of OHGI or the notes thereto, OHGI has no material liabilities, direct or indirect, matured
or un-matured, contingent or otherwise; and

 

    7 

     

    

 

(e) The books and records, financial and
otherwise, of OHGI are in all material aspects complete and correct and have been maintained in accordance with GAAP, consistently
applied throughout the periods involved.

 

3.05 Options or
Warrants.   Except as has or will be disclosed in the SEC Reports, there are no existing options, warrants, calls,
or commitments of any character relating to the authorized and unissued stock of OHGI.

 

3.06 Absence of
Certain Changes or Events. Since September 30, 2017 and except as disclosed in the SEC Reports or as set forth in Section
3.06 of the OHGI Disclosure Schedules hereto:

 

(a) there has not been
(i) any material adverse change in the business, operations, properties, assets or condition of OHGI or (ii) any damage, destruction
or loss to OHGI (whether or not covered by insurance) materially and adversely affecting the business, operations, properties,
assets or condition of OHGI;

 

(b) OHGI has not (i)
amended its certificate of incorporation or by-laws, except as required by this Agreement; (ii) declared or made, or agreed to
declare or make any payment of dividends or distributions of any assets of any kind whatsoever to stockholders or purchased or
redeemed, or agreed to purchase or redeem, any of its capital stock; (iii) waived any rights of value, which in the aggregate are
outside of the ordinary course of business or material considering the business of OHGI; or (iv) made any material change in its
method of management, operation, or accounting;

 

(c) OHGI has not except
as has or will be disclosed in SEC Reports: (i) granted or agreed to grant any options, warrants, or other rights for its stock,
bonds, or other corporate securities calling for the issuance thereof; (ii) borrowed or agreed to borrow any funds or incurred,
or become subject to, any material obligation or liability (absolute or contingent) except liabilities incurred in the ordinary
course of business; (iii) paid or agreed to pay any material obligations or liabilities (absolute or contingent) other than current
liabilities reflected in or shown on the most recent OHGI balance sheet and current liabilities incurred since that date in the
ordinary course of business and professional and other fees and expenses in connection with the preparation of this Agreement and
the consummation of the transaction contemplated hereby; (iv) sold or transferred, or agreed to sell or transfer, any of its assets,
properties, or rights (except assets, properties, or rights not used or useful in its business which, in the aggregate have a value
of less than $1,000), or canceled, or agreed to cancel, any debts or claims (except debts or claims which in the aggregate are
of a value less than $1,000); (v) made or permitted any amendment or termination of any contract, agreement, or license to which
it is a party if such amendment or termination is material, considering the business of OHGI; or (vi) issued, delivered or agreed
to issue or deliver, any stock, bonds or other corporate securities including debentures (whether authorized and unissued or held
as treasury stock), except in connection with this Agreement; and

 

(d)  OHGI has
not become subject to any law or regulation that materially and adversely affects, or in the future, may adversely affect, the
business, operations, properties, assets or condition of OHGI.

 

3.07 Litigation
and Proceedings.  There are no actions, suits, proceedings or investigations pending or, to the knowledge of OHGI, threatened
against OHGI, or affecting OHGI or its properties, at law or in equity, before any court or other governmental agency or instrumentality,
domestic or foreign, or before any arbitrator of any kind. OHGI is not in default with respect to any judgment, order, writ, injunction,
decree, award, rule or regulation of any court, arbitrator, or governmental agency or instrumentality.  

 

3.08 No Conflict
with Other Instruments.  The execution of this Agreement and the consummation of the transactions contemplated by this
Agreement will not result in the breach of any term or provision of, constitute a default under, or terminate, accelerate or modify
the terms of, any indenture, mortgage, deed of trust, or other material agreement or instrument to which OHGI is a party or to
which any of their respective assets, properties or operations are subject.

 

    8 

     

    

 

3.09 Compliance
with Laws and Regulations.  OHGI has complied with all applicable statutes and regulations of any federal, state, or other
applicable governmental entity or agency thereof.  

 

3.10 Approval of
Agreement.  The Board of OHGI and to the extent required, its shareholders have authorized the execution and delivery
of this Agreement by OHGI and have approved this Agreement and the transactions contemplated hereby, except that the shareholders
of OHGI have not granted such requests as might be required for the issuance of shares hereunder as required by NASDAQ. 

 

3.11 Material Transactions
or Affiliations.  Except as set forth in the SEC Reports, there exists no contract, agreement or arrangement between OHGI
(or any predecessor) and any person who was at the time of such contract, agreement or arrangement an officer, director, or person
owning of record or known by OHGI to own beneficially, five percent (5%) or more of the issued and outstanding common shares of
OHGI; and, or, which is to be performed in whole or in part after the date hereof or was entered into since January 1, 2015. No
officer, director, nor any five percent (5%) shareholder(s) of OHGI has, or has had since inception of OHGI, any known interest,
direct or indirect, in any such transaction with OHGI, which was material to the business of OHGI. OHGI has no commitment, whether
written or oral, to lend any funds to, borrow any money from, or enter into any other transaction with, any such affiliated person.

 

3.12 Valid Obligation.
 This Agreement and all agreements and other documents executed by OHGI in connection herewith constitute the valid and binding
obligation of OHGI, enforceable in accordance with its terms, except as may be limited by bankruptcy, insolvency, moratorium or
other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability
of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

 

3.13 Exchange Act
Compliance.  OHGI is in compliance with, and current in, all of the reporting, filing and other requirements under the
Exchange Act, except where a failure to so comply is not reasonably likely to have a Material Adverse Effect on OHGI.

 

3.14 No Brokers.
 Except for the entity or entities that has or have been identified to the Company who has or have or will be paid by OHGI,
OHGI has not retained any broker or finder in connection with any of the transactions contemplated by this Agreement, and OHGI
has not incurred or agreed to pay, or taken any other action that would entitle any person to receive, any brokerage fee, finder’s
fee or other similar fee or commission with respect to any of the transactions contemplated by this Agreement.  

 

3.15 Disclosure.
 All disclosure provided to the Stockholders regarding OHGI, its business and the transactions contemplated hereby, including
the OHGI Disclosure Schedules to this Agreement, furnished by or on behalf of OHGI with respect to the representations and warranties
made herein are true and correct and do not contain any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
In the event that the OHGI Disclosure Schedules are not delivered contemporaneously with the execution of this Agreement, they
shall be delivered as soon as practicable prior to the Closing Date.

 

OHGI acknowledges and
agrees that the Company and its Stockholders have not made, nor is the Company and its Stockholders making, any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth herein.

 

ARTICLE IV 

PLAN OF EXCHANGE

 

4.01 The Exchange.
On the terms and subject to the conditions set forth in this Agreement, on the Closing Date, the Stockholders shall assign, transfer
and deliver to OHGI, free and clear of all security interests, liens, pledges, encumbrances, charges, restrictions or known claims
of any kind, nature, or description, all of the Company Shares. In exchange for the transfer of the Company Shares, OHGI shall
issue and deliver the Cash Exchange Consideration and the Initial Shares to the Stockholders. The Cash Exchange Consideration shall
be delivered to the account designated by the Shareholders within two (2) business days of execution of this Agreement and the
Initial Shares shall be delivered within two (2) weeks of the Closing Date.

 

    9 

     

    

 

4.02 Closing.
 The “Closing” or the “Closing Date” of the transactions contemplated by this Agreement
shall occur on or before March 12, 2018, or such or such other date as the parties shall agree. Such Closing shall take place at
a mutually agreeable time and place, and be conditioned upon all of the conditions of the Exchange being met.

 

4.03 Closing Events.
 At the Closing, OHGI, the Company and its Stockholders shall execute, acknowledge, and deliver (or shall ensure to be executed,
acknowledged, and delivered), any and all certificates, financial statements, Schedules, agreements, resolutions, rulings or other
instruments required by this Agreement to be so delivered at or prior to the Closing, together with such other items as may be
reasonably requested by the parties hereto and their respective legal counsel in order to effectuate or evidence the transactions
contemplated hereby.

 

4.04 Termination.
 This Agreement may be terminated by the Company or OHGI only in the event that the Company or OHGI, as the case may be, does
not meet the conditions precedent set forth in Articles VI and VII. If this Agreement is terminated pursuant to this Section,
this Agreement shall be of no further force or effect, and no obligation, right or liability shall arise hereunder.

 

ARTICLE V 

COVENANTS OF THE PARTIES

 

The parties hereby
agree that:

 

5.01 Audited Financial
Statements.  The Company shall deliver to OHGI no later than seventy (70) days following the consummation of the transaction
contemplated hereby, audited financial statements of the Company for the year ended December 31, 2017, including balance sheets
at December 31, 2017, and 2016, and statements of operations and cash flows for the year ended December 31, 2017, prepared in accordance
with Generally Accepted Accounting Principles (“GAAP”), consistently applied, together with a report of the
auditors of the Company thereon, in such form that will to enable OHGI to file a Form 8-K with the SEC reporting the acquisition
of the Company in accordance with the applicable requirements of the Exchange Act, all at OHGI’s sole cost and expense. The
Company parties agree to exert reasonable best efforts and cooperate in the preparation of such financial statements, including
executing such certificates as may reasonably be requested by the auditors. For further clarification, OHGI agrees to pay the reasonable
fees and costs of the auditor in completing the audit of the Company.

 

5.02 Additional
Shares.

 

(a) Promptly, and in
no event more than forty-five (45) days after the end of the period commencing on the Closing Date and ending at the end of the
calendar month which first ends twelve (12) months after the Closing Date, tentatively, on or about, March 31, 2019 (“First
Adjustment Period”), OHGI shall deliver to the Stockholders, in proportion to their respective Stockholder Percentages,
a number of Additional Shares equal to four (4) times the Company’s net after-tax earnings (“Net Profit”)
for the First Adjustment Period, divided by the Market Value of the OHGI Common Stock, as determined below.

 

(b) Promptly and in
no event more than forty-five (45) days after the end of the period commencing on the day following the First Adjustment Period
and ending twelve (12) months thereafter (tentatively, on or about March 31, 2020) (“Second Adjustment Period”),
OHGI shall deliver to the Stockholders, in proportion to their respective Stockholder Percentages, a number of Additional Shares
equal to four (4) times the Company’s Net Profit for Second Adjustment Period, divided by the Market Value of the OHGI Common
Stock, as determined below; provided that if the Company’s Net Profit for the eighteen (18) months following the Closing
is in excess of $3,000,000, the number of Additional Shares to be delivered to the Stockholders in proportion to their respective
Stockholder Percentages for the Second Adjustment Period shall be equal to five (5) times the Company’s Net Profit for the
Second Adjustment Period, divided by the Market value of the OHGI Common stock, as determined below.

 

    10 

     

    

 

For purposes of the
above:

 

(i)         The
Company’s Net Profit for each of the First Adjustment Period and the Second Adjustment Period shall be determined in accordance
with GAAP. For the avoidance of doubt, Net Profits shall not include any revenues, or costs and expenses, related to OHGI or any
other subsidiary or affiliate thereof other than the Company.

 

(ii)        The
“Market Value” of the OHGI Common Stock used to determine the number of shares of Common Stock deliverable
in respect of the First Adjustment Period or the Second Adjustment Period, as the case may be, shall be the average closing price
of a share of OHGI Common Stock for the ten (10) consecutive trading days (“Determination Period”) ending on
the last day of the First Adjustment Period or the Second Adjustment Period, as the case may be (each, a “Determination
Date”).  

 

(iii)       Closing
price of a share of OHGI Common Stock as of any date during the Determination Period shall mean (A) if the OHGI Common Stock is
then listed on NASDAQ or another securities exchange (each, an “Exchange”), the closing price of the OHGI Common
Stock on the Exchange on which OHGI Common Stock is then listed on such date as reported by Bloomberg L.P. (based on a trading
day from 9:30 a.m. (New York City-time) to 4:02 p.m. (New York City-time); (B) if OHGI Common Stock is quoted on OTCQB, OTCQX or
a similar recognized quotation service (each, a “Quotation Service”), the closing price of a share OHGI Common
Stock on such date as quoted on such Quotation Service ; or (C) if the OHGI Common Stock is not then listed on an Exchange or quoted
for trading on a Quotation Service and if prices for the OHGI Common Stock are then reported by OTC Pink, the price published by
OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), as the last bid
price per share of the OHGI Common Stock so reported for such date; or (D) in all other cases, the fair market value of a
share of OHGI Common Stock as determined by an independent appraiser selected in good faith by the Board of Directors of OHGI,
the fees and expenses of which shall be paid by OHGI.

 

For example, (i) if
the Company’s Net Profit for the First Adjustment Period was $1,000,000 and the Market Value of the OHGI Common Stock was
$1.00, the aggregate number of shares of OHGI Common Stock to be issued to the Stockholders would be 4,000,000 shares, (ii) if
the Company’s Net Profit for the Second Adjustment Period was $4,000,000 and the Market Value of the OHGI Common Stock was
$4.00, the aggregate number of shares of OHGI Common Stock to be issued to the Stockholders would be 4,000,000 shares, and (iii)
if the Company’s Net Profit for the first eighteen (18) months after the Closing was $3,050,000 and the Company’s Net
Profit for the Second Adjustment Period was $4,000,000 and the Market Value of the OHGI Common Stock was $4.00, the aggregate number
of shares of OHGI Common Stock to be issued to the Stockholders would be 5,000,000 shares.

 

OHGI shall cause its
Transfer Agent to issue and deliver certificates evidencing the number of additional shares of OHGI Common Stock, if any, registered
in the names of the Stockholders, to the Stockholders, in proportion to their respective Stockholder Percentages within five (5)
days after the Determination Date (“Issuance Date”).

 

(c) Notwithstanding
anything herein to the contrary, regardless of whether OHGI has a class of securities listed on NASDAQ at the time Additional Shares
are to be issued in respect of the First Adjustment Period and the Second Adjustment Period, the aggregate number of shares of
OHGI Common Stock to be delivered pursuant to this Agreement, including the Initial Shares and the Additional Shares, cannot exceed
19.9% of the total number of shares of the OHGI Common Stock outstanding as of the Closing Date and on the dates of issuance of
Additional Shares unless approved by NASDAQ, which will require a vote of the shareholders of OHGI other than the Stockholders.
If it is necessary under the circumstances for OHGI to obtain approval from its stockholders to permit any issuance of OHGI Common
Stock pursuant to the terms hereof, OHGI agrees to exercise reasonable best efforts to obtain the requisite stockholder approval
and NASDAQ’s approval.

 

If OHGI shall not obtain
such approvals prior to the end of the First Adjustment Period or the Second Adjustment Period and the number of shares of OHGI
Common Stock deliverable pursuant hereto exceeds 19.9% of the total number of shares of OHGI Common Stock outstanding on the date
hereof or on the Issuance Date, OHGI shall pay cash in lieu of delivering any shares of OHGI Common Stock otherwise deliverable.

 

    11 

     

    

 

(d)   The Stockholders
understand and acknowledge that the issuance of shares of OHGI Common Stock pursuant hereto is contingent upon OHGI obtaining NASDAQ
approval. The Stockholders further acknowledge that NASDAQ approval is dependent upon OHGI’s satisfaction of certain
qualifications and requirements imposed by the NASDAQ Capital Market, which may include the approval of the issuance of OHGI common
stock by OHGI’s stockholders.

 

5.03 Reservation
of OHGI Common Stock. OHGI agrees to reserve with its Transfer Agent from time-to-time a sufficient number of shares of OHGI
Common Stock for issuance to the Stockholders pursuant to Section 5.02.

 

5.04 Public Status.
 OHGI shall make any and all required filings under the Exchange Act so that it remains a reporting company under the Exchange
Act and so that the OHGI Common Stock continues to be a publicly-traded security for a period of at least five (5) years from
the Closing Date. OHGI shall exercise commercially reasonable efforts to maintain the listing of the OHGI Common Stock on NASDAQ
during the five (5) years following the Closing Date.        

 

5.05 Public Announcements.
 Except as required by applicable law, OHGI and the Company shall consult with each other before issuing any press release
or making any public statement with respect to this Agreement or the transactions contemplated hereby. The Stockholders shall be
afforded the opportunity for meaningful consultation prior to OHGI issuing any press release or making any public statement should
the contemplated press release or public statement be in reference to such Stockholder in any way.

 

5.06 Notices of
Certain Events.  In addition to any other notice required to be given by the terms of this Agreement, each of the parties
shall promptly notify the other party hereto of:

 

(a) any notice or other
communication from any person alleging that the consent of such person is or may be required in connection with any of the transactions
contemplated by this Agreement;

 

(b) any notice or other
communication from any governmental or regulatory agency or authority in connection with the transactions contemplated by this
Agreement; and

 

(c) any actions, suits,
claims, investigations or proceedings commenced or, to its knowledge threatened against, relating to or involving or otherwise
affecting such party that, if pending on the date of this Agreement, would have been required to have been disclosed pursuant
hereto or that relates to the consummation of the transactions contemplated by this Agreement.  

 

5.07 Access to Information.
 Following the date hereof, until consummation of all transactions contemplated hereby:

 

(a) The Company shall
give to OHGI and its authorized representatives full and complete access to its books and records, contracts, facilities and personnel
as OHGI and its authorized representatives may request so that OHGI may complete its due diligence investigation of the Company. The
officers of the Company agree to provide OHGI and its authorized representatives with access to any information in his or her or
the Company’s possession or within his or her or the Company’s control that contains information generated by him or
her or the Company regarding the Company relative to its financial, operational, and/or regulatory condition (present, past, or
prospective). 

 

(b) OHGI shall give
to the officers and the authorized representatives of the Company full and complete access to the books and records, contracts,
facilities and personnel of OHGI as the officers and the authorized representatives of the Company may request so that the Company
may complete its due diligence investigation of OHGI. OHGI agrees to provide the officers and authorized representatives of the
Company with access to any information in its possession or within its control which contains information generated by it or on
its behalf relative to the financial, operational, and/or regulatory condition (present, past, or prospective) of OHGI.

 

    12 

     

    

 

5.08 Limitation
of Business Activities of the Company Prior to Closing.  Except for transactions contemplated by this Agreement, the Company
will not, without the prior written consent of OHGI, (i) make any material change in the type or nature of its business, or in
the nature of its operations, (ii) create or suffer to exist any debt, other than that currently in existence or undertaken to
complete projects ongoing or to meet short term working capital needs, (iii) issue any securities or membership interests or (iv)
enter into any new agreements of any kind or undertake any new obligations or liabilities likely to have a material impact on its
business.

 

5.09 Consents of
Third Parties.  Each of the parties will give any notices to third parties, and will use its reasonable best efforts to
obtain any third-party consents, that the other parties reasonably may request in connection with this Agreement. Each of the parties
will give any notices to, make any filings with, and use its reasonable best efforts to obtain any authorizations, consents, and
approvals of governments and governmental agencies in connection with the matters in this Agreement.

 

5.10 No Solicitations.
 From and after the date of this Agreement until the later of the Closing, sixty (60) days after the date hereof or termination
of this Agreement pursuant to Section 9.01, the Company will not, and will not permit any of its directors, officers, stockholders,
or agents acting on its behalf to: (i) take any action to solicit, initiate, encourage or assist the submission of any proposal,
negotiation or offer from any person or entity other than OHGI, and other person(s) or entities for purposes of soliciting their
participation as investors or co-investors with the Company, relating to the acquisition, sale or transfer of any of the Company
Shares or any material part of the assets of the Company; (ii) offer to issue, sell or transfer any Company Shares or any material
part of the assets of the Company to any person other than OHGI; or (iii) disclose financial or other information relating to
the Company other than in the ordinary course of business to any person or entity other than OHGI or its agents and representatives,
except with the written consent of OHGI. The Company acknowledges and agrees that the legal remedies available to OHGI in the
event it violates any of the foregoing covenants would be inadequate and that OHGI shall be entitled to specific performance,
injunctive relief and other equitable remedies in the event of any such violation. The Company agrees that it will immediately
notify OHGI regarding any contact between the Company, any of its directors, officers, stockholders, employees, agents or representatives
and any other person regarding any offer, proposal or inquiry during this exclusivity period.  

 

5.11 No Investment
without Consent. Prior to the second (2nd) anniversary of the Closing Date, the Company shall not accept any investment
from a third party without the consent of OHGI.

 

5.12 Short Sale.
Prior to the second (2nd) anniversary of the Closing Date, no Stockholder shall, directly or indirectly, enter into
a short sale of OHGI Common Stock or enter into any hedging transaction including any borrowing which establishes a net short position.

 

5.13 Additional
Acquisitions. Prior to completing an acquisition of another business, OHGI shall advise the Stockholders serving on the Board
of the Company of its intent to do so and, if consummation of such acquisition requires consent of the stockholders of OHGI, such
Stockholders shall have the right to vote any shares of OHGI they may hold on the applicable record date.

 

5.14 Survival.
The obligations of OHGI under this Article V shall survive any termination of this Agreement.

  

ARTICLE VI 

CONDITIONS PRECEDENT TO OBLIGATIONS OF
OHGI

 

The obligations of
OHGI under this Agreement are subject to the satisfaction, at or before the Closing Date, of the following conditions:

 

6.01 Accuracy of
Representations and Performance of Covenants. Each of the representations and warranties made by the Company Parties and the
Stockholders shall be true and correct in all material respects as of the Closing Date as if made on such date.  The Company
and the Stockholders shall have performed or complied with all covenants and conditions required by this Agreement to be performed
or complied with by it prior to or at the Closing. OHGI shall be furnished with a certificate, signed by the Stockholders of the
Company and a duly authorized executive officer of the Company dated as of the Closing Date, confirming (i) the statements made
in the two (2) preceding sentences; and (ii) that there has been no material adverse change in the business, affairs, prospects,
operations, properties, assets or conditions of the Company since the date of this Agreement.

 

    13 

     

    

 

6.02 No Governmental
Prohibition. No order, statute, rule, regulation, executive order, injunction, stay, decree, judgment or restraining order
shall have been enacted, entered, promulgated or enforced by any court or governmental or regulatory authority or instrumentality
that prohibits the consummation of the transactions contemplated hereby.

 

6.03 Consents.
 All consents, approvals, waivers or amendments pursuant to all contracts, licenses, permits, trademarks and other intangibles
in connection with the transactions contemplated herein, or for the continued operation of the Company after the Closing Date on
the basis as presently operated shall have been obtained.

 

6.04 Absence of
Litigation. There shall be no actions, suits, proceedings or governmental investigations or inquiries pending or, to Company’s
knowledge, threatened against the Company and/or its Stockholders, which would prevent the consummation of the transaction contemplated
hereby.

 

6.05 Other Items.
OHGI shall have received further documents, certificates, or instruments relating to the transactions contemplated hereby as it
may reasonably request, including such financial statements for the Company and such information regarding the Company and its
operations as OHGI shall deem reasonably necessary for inclusion in the reports to be filed by OHGI with the SEC.

 

6.06 Schedules and
Other Information.  The Company shall have delivered to OHGI the books and records reasonably requested in connection
with OHGI’s due diligence investigation of the Company, and there shall have been no disclosure provided in connection with
such due diligence investigation, which in the reasonable opinion of OHGI differs materially from the information it has received
as of the date hereof and which does or may have a materially adverse effect on the value of the business of the Company or on
its assets, properties or goodwill.

 

ARTICLE VII 

CONDITIONS PRECEDENT TO OBLIGATIONS
OF 

THE COMPANYAND ITS STOCKHOLDERS

 

The obligations of
the Company and its Stockholders under this Agreement are subject to the satisfaction, at or before the Closing Date, of the following
conditions:

 

7.01   Accuracy
of Representations and Performance of Covenants. Each of the representations and warranties made by OHGI shall be true and
correct in all material respects as of the Closing Date as if made on such date. OHGI shall have performed or complied with all
covenants and conditions required by this Agreement to be performed or complied with by it prior to or at the Closing. The Company
shall be furnished with a certificate, signed by a duly authorized executive officer of OHGI, dated the Closing Date, confirming
(i) the statements made in the two preceding sentences; and (ii) that there has been no material adverse change in the business,
affairs, prospects, operations, properties, assets or conditions of the OHGI since the date of this Agreement.

 

7.02 No Governmental
Prohibition.  No order, statute, rule, regulation, executive order, injunction, stay, decree, judgment or restraining
order shall have been enacted, entered, promulgated or enforced by any court or governmental or regulatory authority or instrumentality,
which prohibits the consummation of the transactions contemplated hereby.

 

7.03 Consents.
 All consents, approvals, waivers or amendments pursuant to all contracts, licenses, permits, trademarks and other intangibles
in connection with the transactions contemplated herein, or for the continued operation of OHGI after the Closing Date shall have
been obtained, except that the consent of NASDAQ to the issuance of the Additional Shares, the consent of the shareholders of OHGI
to the issuance of the Additional Shares and the issuance of the Additional Shares may be obtained or effectuated as otherwise
set forth in Section 5.02.

 

    14 

     

    

 

7.04 Absence of
Litigation. There shall be no actions, suits, proceedings or governmental investigations or inquiries pending or, to OHGI’s
knowledge, threatened against OHGI which would prevent the consummation of the transactions contemplated hereby.

 

7.05 Employment
Agreement. OHGI shall within three (3) business days of the Closing Date, enter into Employment Agreements with Rodriguez,
Nieto and Jacqueline Patricia Rosales (“Rosales”) in the forms to be annexed hereto as Exhibits 7.05A, 7.05B
and 7.05C, respectively, and which Employment Agreements (i) shall be for a minimum period of two (2) years; (ii) shall specify
that the annual salaries for Rodriguez and Nieto respectively will be at a minimum rate of $125,000 annually and that the annual
salary for Rosales will be at a minimum rate of $50,000 annually; (iii) Rodriguez’ Employment Agreement will include an issuance
from OHGI to Rodriguez and/or his designee(s) of 400,000 shares of OHGI common stock within five (5) business days of the ‘Effective
Date’ of such Employment Agreement, which may be issued on an S-8 basis to the extent available subject to any applicable
affiliate rules; and (iv) which such Employment Agreements shall not include any non-compete beyond the minimum two (2) year period
of such Employment Agreements.

 

7.06 Other Items.
 The Company and its Stockholders shall have received further documents, certificates, or instruments relating to the transactions
contemplated hereby as they may reasonably request.

 

7.07 Schedules and
Other Information. OHGI shall have delivered to the Company the OHGI Disclosure Schedules required hereunder, and there shall
have been no disclosure in any Schedule delivered after the date of execution and delivery of this Agreement, or the documents
described therein, which in the reasonable opinion of the Company does or may have a materially adverse effect on the value of
the business of OHGI or on its assets, properties or goodwill.

 

ARTICLE VIII 

POST CLOSING COVENANTS

 

8.01       Cooperation
with Financial Statements. The Company shall, at the expense of OHGI, assist OHGI to complete such audit of the Company’s
financial statements as are required by the Exchange Act.

 

8.02       Information
Statement. As promptly as practicable following the Closing Date, OHGI shall prepare and caused to be mailed to its stockholders
such Information Statement as may be required by the Rules and Regulations of the Exchange Act and the Rules of NASDAQ to permit
the Exchange Shares to be issued to the Stockholders. 

 

8.03       Board
Representation. OHGI shall cause Rodriguez and Nieto to be elected as directors of the Board of the Company; it being understood
that under all circumstances, OHGI will have the right to designate a majority of the members of the Board of the Company. Rodriguez
and Nieto and any other directors or officers of the Company and the Company shall be covered under OHGI’s Directors and
Officers Liability Insurance Policy so long as the Company remains a wholly owned subsidiary of OHGI at OHGI’s sole cost
and expense including any applicable retention amount(s).

 

  

 

8.04       Restriction
on Investment in Company by Third Parties. For a period of three (3) years after the Closing Date, the Company will not accept
investment funds from any third party, or issue any of its securities, or permit the transfer or assignment of any of its securities
without the express written approval of a designated member of the Board of OHGI.

 

8.05       Trading
Restrictions. No stockholder of the Company, whether in such stockholder’s own capacity or through a representative,
agent or affiliate, shall enter into or effect any “short sales” (as that term is defined in Rule 10a-1 of the Exchange
Act) of OHGI Common Stock or any hedging transaction, including obtaining a borrowing, which establishes a net short position with
respect to OHGI Common Stock.

 

8.06       Non-interference.
Subject to the fiduciary obligations of the Board of OHGI, Christopher Robin Rodriguez and Patricia Nieto-Rodriguez shall serve
as the co-Chief Executive Officers of the Company, with sole responsibility and authority for the Company’s obligations for
the term of their Employment Agreements. Further, subject to the fiduciary obligations of the Board of OHGI, neither OHGI nor any
of its affiliated entities shall interfere with the operations of the Company.

 

    15 

     

    

 

ARTICLE IX 

TERMINATION 

 

9.01 Termination.
 This Agreement may be terminated at any time prior to the Closing:

 

(a) by mutual written
consent of OHGI and the Company;

 

(b) by OHGI or the
Company if the Closing shall not have occurred on or before March 12, 2018 (unless the failure to consummate the transactions by
such date shall be due to the action or failure to act of the party seeking to terminate this Agreement which, in the case of the
Company would include the failure of any Stockholder);

 

(c) by OHGI if: (i)
the Company or any of its Stockholders shall have failed to timely comply in any material respect with any of the other covenants,
conditions, terms or agreements contained in this Agreement to be complied with or performed by it, which breach is not cured within
ten (10) days if capable of cure; or (ii) any representations and warranties of the Company Parties or its Stockholders contained
in this Agreement shall have been materially false when made or on and as of the Closing Date; or

 

(d) by the Company
if: (i) OHGI shall have failed to timely comply in any material respect with any of the covenants, conditions, terms or agreements
contained in this Agreement to be complied with or performed by it, which breach is not cured within ten (10) days if capable
of cure; or (ii) any representations and warranties of OHGI contained in this Agreement shall have been materially false when
made or on and as of the Closing Date.  

 

9.02 Effect of
Termination.  In the event of the termination of this Agreement pursuant to this Article IX, all further obligations
of the parties under this Agreement shall forthwith be terminated without any further liability of any party to the other parties;
provided, however, that nothing contained in this Section 9.02 shall relieve any party from liability for any breach of
this Agreement. Upon termination of this Agreement for any reason, each of the parties shall promptly cause to be returned
to the other all documents and information obtained in connection with this Agreement and the transactions contemplated by this
Agreement and all documents and information obtained in connection with the investigation of the other party’s business,
operations and legal affairs, including any copies made of any such documents or information.

 

ARTICLE X 

SURVIVAL OF REPRESENTATIONS AND WARRANTIES;
INDEMNIFICATION

 

10.01. Survival.
The representations and warranties, set forth in this Agreement, in any Exhibit or Schedule hereto and in any certificate or instrument
delivered in connection herewith shall survive for a period of eighteen (18) months after the Closing Date (“Warranty
Period”) and shall thereupon terminate and expire and shall be of no force or effect thereafter, except that (i) the
representation and warranty of the Stockholders in Section 3.01 as to the ownership of the Company Shares shall survive
for the period equal to the applicable statute of limitations relating to said matter; (ii) with respect to any claim, written
notice of which shall have been delivered to OHGI or the Stockholders, as the case may be, in accordance with the indemnification
provisions of this Article X and prior to the end of the Warranty Period, such claim shall survive the termination of such
Warranty Period for as long as such claim is unsettled, and (ii) with respect to any litigation which shall have been commenced
to resolve such claim on or prior to such date.

 

10.02. Indemnification
by Members. Subject to the provisions of Section 10.05 below, each Stockholder hereby covenants and agrees with OHGI
that such Stockholder shall indemnify OHGI and its directors, officers, employees and Affiliates (as that term is defined in Rule
405 of the Securities Act), and each of their successors and assigns (individually, an “OHGI Indemnified Party”),
and hold them harmless from, against and in respect of any and all costs, losses, claims, liabilities, fines, penalties, damages
and expenses (including interest, if any, imposed in connection therewith, court costs and reasonable fees and disbursements of
counsel) (collectively, “Damages”) incurred by any of them resulting from any misrepresentation, breach of any
representation or warranty in this Agreement or the non-fulfillment in any material respect of any agreement, covenant or obligation
by the Stockholders or Members, as the case may be, made in this Agreement (including without limitation any Exhibit or
Schedule hereto and any certificate or instrument delivered in connection herewith).

 

    16 

     

    

 

10.03. Indemnification
by OHGI. Subject to the provisions of Section 10.05 below, OHGI hereby covenants and agrees with the Stockholders that
OHGI shall indemnify the Stockholders (each a “Stockholder Indemnified Party” and collectively, the “Stockholder
Indemnified Parties”) and hold them harmless from, against and in respect of any and all Damages incurred by the Stockholder
Indemnified Party resulting from any misrepresentation, breach of any representation or warranty in this Agreement or the non-fulfillment
in any material respect of any agreement, covenant or obligation by OHGI made in this Agreement (including without limitation any
Exhibit or Schedule hereto and any certificate or instrument delivered in connection herewith).

 

10.04. Right to
Defend. If the facts giving rise to any such indemnification shall involve any actual claim or demand by any third party against
an OHGI Indemnified Party or Stockholder Indemnified Party (referred to herein as an “Indemnified Party”), then
the Indemnified Party will give prompt written notice of any such claim to the indemnifying party, which notice shall set forth
in reasonable detail the nature, basis and amount of such claim (the “Notice of Third Party Claim”). It is a
condition precedent to the applicable indemnifying party’s obligation to indemnify the applicable Indemnified Party for such
claim that such Indemnified Party timely provide to such indemnifying party the applicable Notice of Third Party Claim, provided
that the failure to provide such Notice of Third Party Claim shall only relieve such indemnifying party of its or his obligation
to indemnify for such claim only to the extent that such indemnifying party has been prejudiced by such Indemnified Party’s
failure to give the Notice of Third Party Claim as required. The indemnifying party receiving such Notice of Third Party Claim
may (without prejudice to the right of any Indemnified Party to participate at its own expense through counsel of its own choosing)
undertake the defense of such claims or actions at its expense with counsel chosen and paid by its giving written notice (the “Election
to Defend”) to the Indemnified Party within thirty (30) days after the date the Notice of Third Party Claim is deemed
received; provided, however, that the indemnifying party receiving the Notice of Third Party Claim may not settle such claims or
actions without the consent of the Indemnified Party, which consent will not be unreasonably withheld or delayed, except if the
sole relief provided is monetary damages to be borne solely by the indemnifying party; and, provided further, if the defendants
in any action include both the indemnifying party and the Indemnified Party, and the Indemnified Party shall have reasonably concluded
that counsel selected by the indemnifying party has a conflict of interest because of the availability of different or additional
defenses to the parties, the Indemnified Party shall cooperate in the defense of such claim and shall make available to the indemnifying
party pertinent information under its control relating thereto, but the Indemnified Party shall have the right to retain its own
counsel and to control its defense and shall be entitled to be reimbursed for all reasonable costs and expenses incurred in such
separate defense. In no event will the provisions of this Article reduce or lessen the obligations of the parties under
this Article, if prior to the expiration of the foregoing thirty (30) day notice period, the Indemnified Party furnishing the Notice
of Third Party Claim responds to a third-party claim if such action is reasonably required to minimize damages or avoid a forfeiture
or penalty or because of any requirements imposed by law. If the indemnifying party receiving the Notice of Third Party Claim does
not duly give the Election to Defend as provided above, then it will be deemed to have irrevocably waived its right to defend or
settle such claims, but it will have the right, at its expense, to attend, but not otherwise to participate in, proceedings with
such third parties; and if the indemnifying party does duly give the Election to Defend, then the Indemnified Party giving the
Notice of Third Party Claim will have the right at its expense, to attend, but not otherwise to participate in, such proceedings.
The parties to this Agreement will not be entitled to dispute the amount of any Damages (including reasonable attorney’s
fees and expenses) related to such third-party claim resolved as provided above.

 

10.05 Limitation
on Rights of Indemnification.

 

(a) No OHGI Indemnified
Party shall have the right to indemnification under this Agreement unless and until the aggregate amount of any and all such indemnification
claims made by an OHGI Indemnified Party under this Agreement exceeds $100,000 (the “Basket”). If claims asserted
by the OHGI Indemnified Parties exceed the Basket, OHGI Indemnified Parties shall be entitled to receive $1.50 USD in respect of
each one dollar ($1.00 USD) of indemnified claims in excess of the Basket until the OHGI Indemnified Parties shall have received
an amount equal to the sum of the reimbursed indemnified claims plus the Basket in respect of indemnified claims If OHGI Indemnified
Parties are entitled to any further payments in respect of indemnifications claims, they shall be made on a dollar-for-dollar basis
subject to any limitations contained herein. The Basket shall not apply to claims relating to the representation and warranty of
the Stockholders in Section 2.01 as to the ownership of the Company Shares.

 

    17 

     

    

 

Stockholders may satisfy
any indemnification claims hereunder by delivery of shares of OHGI Common Stock. Such shares shall be valued at the greater of
(i) $1.50 USD per share and (ii) the value used to determine the number of shares issued in respect of the Additional Shares, and,
in such latter case, shares shall be valued first at the highest price, up to the number of shares issued at such price, next at
the second highest price, up to the number of shares issued at such price, and then at the lowest price.

 

(b) The aggregate liability
of the Stockholders pursuant to this Article X shall not exceed the sum of the Cash Exchange Consideration and the value of the
Exchange Shares received by them; provided, however, that the provisions of this Section 10.05(b) shall not apply to: (i)
breaches of Stockholders’ representations and warranties relating to ownership of Company Shares, and (ii) claims arising
out of fraud.

 

(c) Except in the event
of fraud, the remedies provided in Sections 10.02 and 10.03 hereof shall be the sole and exclusive remedies of OHGI Indemnified
Parties and Stockholder Indemnified Parties from and after the Closing in connection with any breach of representation or warranty
or non-performance, partial or total, of any covenant or agreement contained in this Agreement; provided, that, nothing contained
herein shall prevent any party from seeking equitable remedies (including specific performance or injunctive relief) in connection
therewith.

 

ARTICLE XI 

MISCELLANEOUS

 

11.01 Governing
Law.  This Agreement shall be governed by, enforced, and construed under and in accordance with the laws of New York,
without giving effect to principles of conflicts of law thereunder. Venue for all matters shall be in New York, New York. Each
of the parties irrevocably consents and agrees that any legal or equitable action or proceedings arising under or in connection
with this Agreement shall be brought exclusively in the Southern District Court of the United States located in New York County.
By execution and delivery of this Agreement, each party hereto irrevocably submits to and accepts, with respect to any such action
or proceeding, generally and unconditionally, the jurisdiction of the aforesaid court, and irrevocably waives any and all rights
such party may now or hereafter have to object to such jurisdiction.

 

11.02 Notices.
 Any notice or other communications required or permitted hereunder shall be in writing and shall be sufficiently given if
personally delivered to it or sent by overnight courier or registered mail or certified mail, postage prepaid, or electronic mail
with a follow up copy by overnight courier, addressed as follows:

 

If to the Company or
the Stockholders:

 

C-Rod, Inc. 

649 NE 81st Street 

Miami, Florida 33138 

Attn: Christopher Robin Rodriguez, President 

E-mail: donchrisrodriguez@gmail.com

 

with a copy (which shall not constitute
notice) by electronic mail to:

 

If to OHGI:

 

One Horizon Group,
Inc. 

Room 1808, 18/F Hutchison House, 10 Harcourt
Road, Central 

Hong Kong 

Attn: Mark B. White, Chief Executive Officer 

E-mail: mark@onehorizoninc.com

 

    18 

     

    

 

with a copy (which shall not constitute
notice) by electronic mail to:

 

One
Horizon Group, Inc.

34 South Molton Street

London W1K 5RG, United Kingdom

Attn: Martin Ward, Chief Financial Officer 

E-mail: martin.ward@onehorizoninc.com

 

Mandelbaum Salsburg P.C. 

1270 Avenue of the Americas, Suite 1808 

New York, NY 10020 

Attention: Vincent J. McGill, Esq. 

E-mail: vmcgill@lawfirm.ms

 

or such other addresses as shall be furnished
in writing by any party in the manner for giving notices hereunder, and any such notice or communication shall be deemed to have
been given (i) upon receipt, if personally delivered or sent by electronic mail, (ii) on the day after dispatch, if sent by overnight
courier, and (iii) three (3) days after mailing, if sent by registered or certified mail.

 

11.03 Attorney’s
Fees.  In the event that either party institutes any action or suit to enforce this Agreement or to secure relief from
any default hereunder or breach hereof, the prevailing party shall be reimbursed by the losing party for all costs, including reasonable
attorney’s fees, incurred in connection therewith and in enforcing or collecting any judgment rendered therein.

 

11.04 Confidentiality.
OHGI, on the one hand, the Company and its Stockholders, on the other hand, each agree with the other that the
documentation and other information disclosed to them by the other party hereunder to evaluate various the business and affairs
of the Company or OHGI, as the case may be, and various aspects of the Exchange and the other transactions contemplated hereby
may contain proprietary confidential information and trade secrets, and that the disclosure and unauthorized use of such information
could cause irreparable injury. The parties agree that all such information and materials shall be used and disclosed
only to the limited extent necessary for the parties hereto (and their professional advisors) to evaluate the Exchange and the
other transactions contemplated hereby. All extracts, digests and copies of such documentation and information shall be maintained
under strict control by the recipients. Upon termination of the negotiations by the parties, no party (or advisor to such party)
shall make any further use of such documentation and information, and
all documentation previously obtained (together with all copies, abstracts, digests and analyses thereof) shall be returned to
the party providing such information. The Company and its Stockholders recognize that OHGI is a publicly traded company in the
United States and agree not to buy OHGI Common Stock or recommend to any other party that it or he or she do so, from the Closing
Date until such information has been disclosed to the public. 

 

11.05 Public Announcements
and Filings.  Unless required by applicable law or regulatory authority, none of the parties will issue any report, statement
or press release to the general public, trade or trade press, or to any third party (other than its advisors and representatives
in connection with the transactions contemplated hereby) or file any document, relating to this Agreement and the transactions
contemplated hereby, except as may be mutually agreed by the parties. Copies of any such filings, public announcements or disclosures,
including any announcements or disclosures mandated by law or regulatory authorities, shall be delivered to each party prior to
the release thereof. 

 

11.06 Schedules;
Knowledge.  Each party is presumed to have full knowledge of all information set forth in the other party’s schedules
delivered pursuant to this Agreement.

 

11.07 Third Party
Beneficiaries.  This contract is strictly between OHGI, the Company and its Stockholders, and, except as specifically
provided, no director, officer, stockholder, employee, agent, independent contractor or any other person or entity shall be deemed
to be a third-party beneficiary of this Agreement.

 

    19 

     

    

 

11.08 Expenses.
 Whether or not the Exchange is consummated, each of OHGI, on the one hand, and the Company, on the other hand, will bear
their own respective expenses, including without limitation the fees and expenses of its legal, accounting and financial advisors,
incurred in connection with the Exchange or any of the other transactions contemplated hereby.

 

11.09 Entire Agreement.
 This Agreement represents the entire agreement between the parties relating to the subject matter thereof and supersedes
all prior agreements, understandings and negotiations, written or oral, with respect to such subject matter.

 

11.10 Amendment
or Waiver.  Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred
herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any party of the performance of any obligation
by the other shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing.
This Agreement may by amended only by a writing signed by all parties hereto.

 

11.11. Best Efforts.
 Subject to the terms and conditions herein provided, each party shall use its best efforts to perform or fulfill all conditions
and obligations to be performed or fulfilled by it under this Agreement so that the transactions contemplated hereby shall be consummated
as soon as practicable. Each party also agrees that it shall use its best efforts to take, or cause to be taken, all actions and
to do, or cause to be done, all things necessary, proper or advisable under applicable laws and regulations to consummate and make
effective this Agreement and the transactions contemplated herein.

 

11.12 Counterparts.
 This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken
together shall be but a single instrument.

 

Signature Page 21 Follows

 

    20 

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed
this Agreement as of the date first-above written.

 

	 	One Horizon Group, Inc.
	 	 	 
	 	By: 	/s/ Mark White
	 	 	Name: Mark White
	 	 	Title: Chief Executive Officer 

 

	 	C-Rod, Inc.
	 	 	 
	 	By: 	/s/ Christopher Robin Rodriguez
	 	 	Name: Christopher Robin Rodriguez
	 	 	Title: Co-Chief Executive Officer 

 

	 	Stockholders:
	 	 	 
	 	/s/
    Christopher Robin Rodriguez
	 	Christopher Robin Rodriguez
	 	 	 
	 	 /s/ Patricia Nieto Rodriguez
	 	Patricia Nieto Rodriguez

 

    21 

     

    

 

Company Disclosure Schedules

 

    22 

     

    

 

OHGI Disclosure Schedules

 

    23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]